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ASD

:   autism spectrum disorder

ADHD

:   attention deficit hyperactivity disorder

CNV

:   copy number variation

ChIP

:   chromatin immunoprecipitation

CON

:   Control

DIOPT

:   *Drosophila* RNAi Screening Center Integrative Ortholog Prediction Tool

DNV

:   de novo variations

FDR

:   false discovery rate

FPKM

:   fragments per kilobase million

GWAS

:   genome‐wide association study

HMG

:   high‐mobility‐group

ID

:   intellectual disability

MAF

:   minor allele frequency

MSET

:   modular single‐set enrichment test

NPCs

:   neural progenitor cells

PCW

:   postconceptional week

PGC

:   psychiatry genomics consortium

PMI

:   post mortem interval

RAS

:   renin angiotensin system

RDNV

:   rare de novo variation

RPKM

:   reads per kilobase million

RVIS

:   residual variation intolerance score

SHR

:   spontaneously hypertensive rat

TF

:   transcription factor

TSS

:   transcription start site

WGCNA

:   weighted gene coexpression network analysis

1. BACKGROUND {#ajmgb32704-sec-0001}
=============

Sex impacts the brain\'s structure and functional organization, as reflected by differences in neuropsychiatric disorders between the sexes (Joel & McCarthy, [2017](#ajmgb32704-bib-0055){ref-type="ref"}). Accordingly, several brain regions that demonstrate sexual dimorphism have already been associated with psychiatric disorders, suggesting that sex is an underlying factor in their prevalence. For example, neurodevelopmental disorders, such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schizophrenia, are more prevalent in men (Bale & Epperson, [2015](#ajmgb32704-bib-0007){ref-type="ref"}).

This sexual dimorphism in brain gene expression reflects differences in the regulatory mechanisms that could be attributed to either hormonal regulation or chromosome complement. The use of "four core genotypes" mice models revealed that sexual dimorphism is not exclusively hormone‐dependent (Arnold & Chen, [2009](#ajmgb32704-bib-0005){ref-type="ref"}). The gene dosage effect of the sex chromosomes is attributed to several mechanisms, such as Y‐linked genes, X‐linked genes, mosaicism, skewed X‐inactivation, X imprinting and heterochromatin sink (Ober, Loisel, & Gilad, [2008](#ajmgb32704-bib-0088){ref-type="ref"}; Schaafsma & Pfaff, [2014](#ajmgb32704-bib-0110){ref-type="ref"}).

The regulatory roles of the Y chromosome on autosomal/X‐linked genes have also been described (Bellott et al., [2014](#ajmgb32704-bib-0009){ref-type="ref"}; Case et al., [2013](#ajmgb32704-bib-0020){ref-type="ref"}; Lemos, Branco, & Hartl, [2010](#ajmgb32704-bib-0066){ref-type="ref"}). In *Drosophila melanogaster*, for example, a class of autosomal/X genes has been reported to consistently change expression levels across multiple Y introgression experiments (Branco, Tao, Hartl, & Lemos, [2013](#ajmgb32704-bib-0015){ref-type="ref"}; Lemos, Araripe, & Hartl, [2008](#ajmgb32704-bib-0065){ref-type="ref"}; Sackton & Hartl, [2013](#ajmgb32704-bib-0105){ref-type="ref"}). Moreover, a set of autosomal genes was sensitive to the sex chromosome complement in mice (Wijchers et al., [2010](#ajmgb32704-bib-0137){ref-type="ref"}). Recent studies regarding brain sexual dimorphism noted several differences in gene expression regulatory mechanisms (e.g., genetic and epigenetic factors; Chen et al., [2016](#ajmgb32704-bib-0023){ref-type="ref"}) that could contribute to sex‐biased prevalence in neuropsychiatric disorders (Ratnu, Emami, & Bredy, [2017](#ajmgb32704-bib-0098){ref-type="ref"}).

In this context, two members of the SOX gene family, *SOX3* and *SRY*, can contribute to these differences. The *SOX3* gene, which is located at the X chromosome, plays a critical role in the central nervous system and hypothalamic development (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}; Brunelli, Casey, Bell, Harland, & Lovell‐Badge, [2003](#ajmgb32704-bib-0016){ref-type="ref"}; Cheah & Thomas, [2015](#ajmgb32704-bib-0022){ref-type="ref"}; Topalovic et al., [2017](#ajmgb32704-bib-0123){ref-type="ref"}) and undergoes dosage compensation in females (Graves, [2015](#ajmgb32704-bib-0044){ref-type="ref"}). The *SRY* gene is located at the Y chromosome and evolved from *SOX3* (Cortez et al., [2014](#ajmgb32704-bib-0028){ref-type="ref"}; Foster & Graves, [1994](#ajmgb32704-bib-0039){ref-type="ref"}; Skaletsky et al., [2003](#ajmgb32704-bib-0115){ref-type="ref"}), sharing an high‐mobility‐group (HMG) box domain that is highly conserved among species (Bergstrom, Young, Albrecht, & Eicher, [2000](#ajmgb32704-bib-0011){ref-type="ref"}).

The *Sry locus* is primarily known as the developmental switch responsible for testes determination. It is transcribed in males at specific periods, even in tissues that are not involved in gonad sexual differentiation (Mayer, Mosler, Just, Pilgrim, & Reisert, [2000](#ajmgb32704-bib-0076){ref-type="ref"}; Turner, Ely, Prokop, & Milsted, [2011](#ajmgb32704-bib-0125){ref-type="ref"}). For example, increased *SRY* expression was observed after induced differentiation into human dopaminergic neurons (Czech et al., [2012](#ajmgb32704-bib-0030){ref-type="ref"}), and it also modulates dopamine biosynthesis through *MAOA* (Dewing et al., [2006](#ajmgb32704-bib-0033){ref-type="ref"}) and *Th* regulation (Milsted et al., [2004](#ajmgb32704-bib-0082){ref-type="ref"}). Few studies have explored its role in neurodevelopment, however, it seems to be crucial for brain development (Loke, Harley, & Lee, [2015](#ajmgb32704-bib-0072){ref-type="ref"}).

The contributions of the *Sry locus* to the hypertensive phenotype are well established in the spontaneously hypertensive rat (SHR), which has also been used as a model for neurodevelopmental disorders more prevalent in males due the presence of symptoms related to ADHD (Sagvolden, Russell, Aase, Johansen, & Farshbaf, [2005](#ajmgb32704-bib-0106){ref-type="ref"}) and ASD (Zhang‐James et al., [2014](#ajmgb32704-bib-0146){ref-type="ref"}).

Differences between *SRY* and *SOX3* are likely related to distinct domains outside the HMG box, as a chimeric *SRY* with *SOX3*‐HMG‐box domain rescued SRY protein regulation function (Bergstrom et al., [2000](#ajmgb32704-bib-0011){ref-type="ref"}). Ectopic *Sox3* expression in bipotential gonad cells (which can differentiate into either testis or ovary) caused XX male reversal in mice (Sutton et al., [2011](#ajmgb32704-bib-0118){ref-type="ref"}), suggesting that *SOX3* and *SRY* target a set of common genes. *Sry* expression in the kidney is also involved in sex‐specific regulation of the blood pressure by the renin‐angiotensin system (RAS), showing activation of the *REN* promoter, while SOX3 inhibits it (Araujo et al., [2015](#ajmgb32704-bib-0002){ref-type="ref"}). Collectively, these data suggest that the regulation exerted by SRY plays a role in sexual differentiation that is not dependent on circulating gonadal hormones and that the association of both transcription factors (TFs) could act as a regulatory mechanism.

We hypothesized that SOX3, SRY or both could differentially regulate sets of genes, according to cell type, brain region and developmental time; these sets of genes act as regulators of the normal differences between the sexes during development. In that case, exclusive SRY and SOX3/SRY target genes could be potentially associated with sex‐biased neurodevelopmental disorders. Using an integrated bioinformatics approach, we identified the target genes of SOX3 and/or SRY. Next, we evaluated the expression level and regulation of these genes in brain samples. Finally, we used ASD gene databases to access whether SOX3 and/or SRY target genes were enriched for this sex‐biased neurodevelopmental disorder. By providing evidence of the differential regulation exerted by SOX3 and/or SRY targets during neurodevelopment, our findings provide insights into a mechanism through which sex factors may contribute to ASD male predisposition and provide a new perspective for studies of other sex‐biased neurodevelopmental disorders.

2. METHODS {#ajmgb32704-sec-0002}
==========

2.1. ChIP‐seq/chip annotation and peak datasets {#ajmgb32704-sec-0003}
-----------------------------------------------

Using published datasets of SRY and SOX3 ChIP‐seq/chip, we identified putative targets of SRY and SOX3 regulation by annotating each peak to the nearest gene provided by RefSeq/UCSC genome annotation databases, according to the corresponding gene assembly using BEDTools (v.2.25.0; Quinlan & Hall, [2010](#ajmgb32704-bib-0096){ref-type="ref"}). To explore SRY, we used three published ChIP‐chip datasets from human, mouse and rat organisms. The human SRY ChIP‐chip was performed using embryonic carcinoma cells (Ntera2) in NimbleGen Array Service onto 1.5‐kb human promoter arrays composed of 23,467 EntrezGenes. From these genes, 1,280 genes were identified among 1,343 SRY peaks (Jin, O\'Geen, Iyengar, Green, & Farnham, [2007](#ajmgb32704-bib-0053){ref-type="ref"}).

A second dataset from mouse SRY ChIP‐chip used embryonic (E11.5) gonadal cells in a 385K RefSeq Promoter Array of MM8 assembly composed of the closest 27,530 RefSeq genes, corresponding to 18,878 mouse EntrezGenes (Li, Zheng, & Lau, [2014](#ajmgb32704-bib-0070){ref-type="ref"}). From these, 3,738 genes were identified among 3,083 SRY peaks. The third dataset from rat SRY ChIP‐chip used embryonic (E13) gonadal cells in Nimblegene\'s Rat ChIP‐chip 3x720K RefSeq Promoter Array, composed of the closest 16,168 RefSeqs genes, and 252 genes were identified in analyses of the 262 possible SRY peaks (Bhandari, Haque, & Skinner, [2012](#ajmgb32704-bib-0012){ref-type="ref"}). Finally, two studies were used for SOX3 ChIP‐seq annotation, and both used neural progenitor cells (NPCs). We found 9,719 peaks corresponding to the closest 7,984 RefSeq genes and 5,307 EntrezGenes in the first study (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}) and 8,067 peaks corresponding to closest 7,523 RefSeq genes and 5,150 EntrezGenes in the second study (McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}).

The *Drosophila* RNAi Screening Center Integrative Ortholog Prediction Tool (DIOPT; Hu et al., [2011](#ajmgb32704-bib-0052){ref-type="ref"}) was used to identify orthologs between mice and human, applying the *best match* criterion. This tool uses ten orthology prediction algorithms across species, four based on phylogenetic models (Phylome, TreeFam, EnsemblCompara, OrthoDB), five based on sequence similarity (Homologene, OMA, Roundup, InParanoid, OrthoMCL) and one based on network protein--protein interactions (Isobase). For ortholog genes in rats, only Compara (BioMart) was used (Vilella et al., [2009](#ajmgb32704-bib-0128){ref-type="ref"}).

To build the SRY and SOX3 peaks datasets, we used the LiftOver tool (Rosenbloom et al., [2014](#ajmgb32704-bib-0103){ref-type="ref"}) to convert the genome coordinates of each species to human hg19 assembly, using default parameters. This process resulted in 4,486 SRY peaks (1,343 from humans, 2,956 from mice and 187 from rats) and 14,032 SOX3 peaks converted from a mouse model, 5,385 from Bergsland et al. ([2011](#ajmgb32704-bib-0010){ref-type="ref"}) and 8,647 from McAninch & Thomas ([2014](#ajmgb32704-bib-0077){ref-type="ref"}).

2.2. Random peak sets and enrichment analysis {#ajmgb32704-sec-0004}
---------------------------------------------

Datasets from SRY and SOX3 peaks were used to build 1,000 random peak sets with the same chromosome distribution and length and number of peaks, using the shuffleBed function in BEDTools (Quinlan & Hall, [2010](#ajmgb32704-bib-0096){ref-type="ref"}). The empirical *p* value was calculated as a proportion of the number of random sets that resulted in overlaps that were equal to or greater than the group compared.

2.3. Databases {#ajmgb32704-sec-0005}
--------------

A summary table concerning the datasets provided by individual studies used in this study is available in Supporting Information [Table S1](#ajmgb32704-supitem-0002){ref-type="supplementary-material"}.

### 2.3.1. Gene expression datasets from mouse brains {#ajmgb32704-sec-0006}

Two expression datasets of mouse brain were used. The first dataset was composed of seven developmental stages (four embryonic stages \[E11.5, E13.5, E15.5, E18.5\] and three postnatal stages \[P4, P14, and P28\]) and four brain structures analyzed through in situ hybridization (midbrain, forebrain, hindbrain and spinal cord). The analysis revealed 1,721 genes, represented by 1,715 EntrezGenes, which were expressed in at least one stage (Thompson et al., [2014](#ajmgb32704-bib-0121){ref-type="ref"}).

The second dataset was composed of the following: (a) a pool of five primary brain cell cultures from postnatal day 1 (P1), containing expression data of astrocytes and oligodendrocytes (divisions 1, 2.5 and 4), (b) a pool of three brain samples from embryos (16.5 postconceptional days) to explore cortical neurons, and (c) adult microglia obtained from P60, resulting in 19,501 identified transcripts (19,427 genes; Sharma et al., [2015](#ajmgb32704-bib-0114){ref-type="ref"}). We selected transcripts with expression data available for at least one sample ≥1 RPKM (reads per kilobase per million) using 21 samples (triplicates of each cell type: microglia, astrocyte, three divisions of oligodendrocytes and two from cortical neurons), totaling 14,109 transcripts (14,102 genes). The combined datasets resulted in 14,526 genes expressed in the brain samples.

### 2.3.2. Tissue‐specific gene expression {#ajmgb32704-sec-0007}

Our analysis included data from a database composed of 842 Ensembl genes and their expression in 13 tissues obtained from 103 C57BL/6 mice samples and 348 human samples. These samples demonstrated similar tissue‐specific expression patterns across mouse and human genes (Lin et al., [2014](#ajmgb32704-bib-0071){ref-type="ref"}). The genes were reannotated, resulting in 840 EntrezGenes across the following tissues: adrenal (2 genes), brain (162 genes), kidney (44 genes), liver (89 genes), lung (14 genes), mammary (2 genes), muscle (51 genes), ovary (2 genes), sigmoid (11 genes), spleen (4 genes), small bowel (15 genes), stomach (11 genes), and testis (430 genes).

### 2.3.3. Cell type specificity measurement {#ajmgb32704-sec-0008}

The cell‐type‐specific gene expression patterns were measured using an adapted Shannon\'s entropy calculation (Schug et al., [2005](#ajmgb32704-bib-0112){ref-type="ref"}) in a published dataset containing gene expression data from the mouse brain samples (Sharma et al., [2015](#ajmgb32704-bib-0114){ref-type="ref"}). Only transcripts that showed expression in at least two of the three replicates, in no less than one cell type, were considered for the analysis. We used the median expression value in each cell type. Only transcripts with H ≤ 2 and Q value ≤7 were considered for further analysis. Low H values indicated that the transcript is expressed in few cell types, and low Q values indicated that it was highly expressed in a specific cell type. This analysis resulted in 2,907 genes with a cell‐type‐specific pattern (lowest Q values) for the following cell types: adult microglia (821 genes), cortical neurons div 05 (283 genes) and division 10 (595 genes), oligodendrocytes div 01 (107 genes), division 2.5 (100 genes), division 04 (180 genes), and astrocytes (821 genes).

### 2.3.4. Gene expression datasets from human brains {#ajmgb32704-sec-0009}

The BrainSpan Atlas database was used to select genes that demonstrated at least 1 RPKM in any brain region, in at least one sample (Miller et al., [2014](#ajmgb32704-bib-0081){ref-type="ref"}). It included 383 samples of 32 individuals (19 males and 13 females) from 8 postconceptional weeks (PCW) to 7 years old. Gene annotation was performed using BioMart (Guberman et al., [2011](#ajmgb32704-bib-0045){ref-type="ref"}) and [org.Hs.eg](http://org.hs.eg).db (Carlson, [2015](#ajmgb32704-bib-0019){ref-type="ref"})*,* both in R (R Core Team, [2015](#ajmgb32704-bib-0097){ref-type="ref"}). In total, 27,636 Ensembl transcripts (20,283 EntrezGenes) were considered for the analyses. To study the differences between sexes, we performed an enrichment analysis between the sex differentially expressed genes and SOX3/SRY target genes. These sex differentially expressed genes (FDR \< 0.01, fold difference \> 2; 122 with higher expression in males and 37 with higher expression in females) were identified by Kang et al. ([2011](#ajmgb32704-bib-0056){ref-type="ref"}) in an analysis of human brain samples from 16 brain regions collected from 31 males and 26 females between the ages of 5.7 PCW and 82 years.

To investigate the differences in DNA methylation during brain development, we used previously published methylation data from 100 males and 79 females brain samples. These samples aged from 23 to 184 postconceptional days, interrogating 8,059 CpG sites modulated during brain development (Spiers et al., [2015](#ajmgb32704-bib-0116){ref-type="ref"}). There were 521 CpG sites located on autosomes (from 8,059 probes, Bonferroni‐corrected *p* value\<1.22E−7), consisting of 389 CpG sites located next to unique genes and 118 in intergenic regions. All coordinates from the CpG sites were annotated using the human genome reference (hg19).

### 2.3.5. ASD risk genes and variants {#ajmgb32704-sec-0010}

For the ASD databases, we used the SFARI Gene database (Abrahams et al., [2013](#ajmgb32704-bib-0001){ref-type="ref"}), with four different levels of stringency thresholds: scores 1 and 2 with genes associated with syndromes (n = 84), scores 1 and 2 without genes associated with syndromes (n = 56), scores 1, 2, 3 and 4 with genes associated with syndromes (n = 665) and scores 1, 2, 3 and 4 without genes associated with syndromes (n = 598). In addition, we included an exome dataset with 12,510 *de novo* mutations found in individuals with autism (9,293 mutations) and their unaffected sibling controls (3,217 mutations), as reported by Sanders and collaborators (Sanders et al., [2015](#ajmgb32704-bib-0107){ref-type="ref"}). This dataset contained 4,620 samples from 3,152 affected individuals and 1,468 controls from the Simon Simplex Collection (SSC) and the Autism Sequencing Consortium (ASC). We also used a dataset from the PGC‐ASD consortium (Autism Spectrum Disorder Working Group of the Psychiatry Genomics Consortium, [2015](#ajmgb32704-bib-0006){ref-type="ref"}) containing GWAS data from 5,305 ASD‐diagnosed cases and 5,305 pseudo controls of European descent (PGC ASD Euro). To select the SNPs for our study, we used a previous study that calculated the polygenic risk for ASD (AUT8; Cross‐Disorder Group of the Psychiatric Genomics Consortium, [2013](#ajmgb32704-bib-0029){ref-type="ref"}). We used only those SNPs that presented an association with a *p* value ≤10E−5, resulting in 20 genes and 10 genes. Additionally, we utilized an exome dataset of genes associated with developmental disorders and intellectual disability through *de novo* variant enrichment (*n* = 94; DDD; McRae et al., [2017](#ajmgb32704-bib-0080){ref-type="ref"}). We used 140,556 *de novo* mutations from whole genome sequencing (Yuen et al., [2017](#ajmgb32704-bib-0144){ref-type="ref"}) from simplex and multiplex families composed of 2,062 males (1,388 probands and 674 affected siblings) individuals and 558 females (353 probands and 205 affected siblings).

### 2.3.6. Residual variation intolerance score (RVIS) {#ajmgb32704-sec-0011}

To select genes intolerant to mutation, we used the RVIS applied to the ESP6500 population (Petrovski, Wang, Heinzen, Allen, & Goldstein, [2013](#ajmgb32704-bib-0092){ref-type="ref"}). Genes within the 25th percentile, representing the most intolerant genes with three cut‐offs, according to MAF (*Minor Allele Frequency*; MAF ≤ 0.01, 0.01 \< MAF ≤ 0.1, or 0.1 \< MAF ≤ 1), were selected, resulting in 473, 350, and 332 genes, respectively.

2.4. Enrichment analysis {#ajmgb32704-sec-0012}
------------------------

To perform the MSET analysis (Eisinger, Saul, Driessen, & Gammie, [2013](#ajmgb32704-bib-0037){ref-type="ref"}), we selected the background genes from chip annotation (GPL18145‐6740). Genes were reannotated using RefSeq genes from UCSC (Rosenbloom et al., [2014](#ajmgb32704-bib-0103){ref-type="ref"}). In total, chip annotation represented 27,530 RefSeq genes corresponding to 18,878 EntrezGenes in mouse UCSC mm9. For the ChIP‐seq analysis, we used the entire background of UCSC mm9, resulting in 24,467 EntrezGenes. Using a human model, genes from ChIP‐chip were annotated using RefSeq UCSC hg19, corresponding to 20,378 EntrezGenes. All analyses were performed with 10,000 permutations to calculate the *p* value using the MSET algorithm. To perform permutations, the algorithm resamples 10,000 times the same number of entries using the entire background, empirically calculating the *p* value, according to the number of random sets that reached the same or greater numbers of overlaps divided by the number of permutations (Eisinger et al., [2013](#ajmgb32704-bib-0037){ref-type="ref"}). The empirical *p* value were adjusted for multiple testing using FDR in R (R Core Team, [2015](#ajmgb32704-bib-0097){ref-type="ref"}). For functional enrichment analyses, we used WebGestalt (Wang, Duncan, Shi, & Zhang, [2013](#ajmgb32704-bib-0132){ref-type="ref"}) with the whole genome as the background. We considered those categories with at least five genes and an adjP ≤ 0.05 (after the Benjamini--Hochberg correction) to be significant. We generated word clouds using <https://www.wordclouds.com/>.

2.5. STRING analysis and TF annotation {#ajmgb32704-sec-0013}
--------------------------------------

STRING (Szklarczyk et al., [2017](#ajmgb32704-bib-0119){ref-type="ref"}) analyses were performed using either SRY or SOX3 proteins as seeds, with up to 100 neighbors. All types of evidence were included, with a minimum confidence level of 0.4. Transcription binding factor data were obtained using the TF checkpoint database (Chawla, Tripathi, Thommesen, Lægreid, & Kuiper, [2013](#ajmgb32704-bib-0021){ref-type="ref"}), which includes nine different databases composed of 3,479 TFs. To assign the motif domain in TF enrichment analysis to the proper TF, we used the UniProt domain or the TF name and searched for it in the TRANSFAC v7.0 public database (Matys et al., [2006](#ajmgb32704-bib-0075){ref-type="ref"}).

2.6. Coexpression network analysis {#ajmgb32704-sec-0014}
----------------------------------

We used previously published male prefrontal cortex samples consisting of 12 ASD‐affected and 15 controls (CON) from GSE28521, containing the expression data of 10,769 probes (9,742 unique EntrezGenes; Voineagu et al., [2011](#ajmgb32704-bib-0129){ref-type="ref"}). Only SRY/SOX3 related genes expressed in the brain dataset were selected, resulting in 1,262 probes. Probes representing the same genes were averaged (*n* = 1,097), and those expressed in at least 50% of the samples from each group were selected, resulting in 1,036 genes. The Weighted Gene Coexpression Network Analysis (WGCNA) was applied to the expression data to build an unsigned coexpression network to characterize the features of the coexpressed gene modules (Langfelder & Horvath, [2007](#ajmgb32704-bib-0061){ref-type="ref"}, [2008](#ajmgb32704-bib-0062){ref-type="ref"}; Langfelder, Luo, Oldham, & Horvath, [2011](#ajmgb32704-bib-0063){ref-type="ref"}). Further methodological details are available in the Supporting Information .

3. RESULTS {#ajmgb32704-sec-0015}
==========

3.1. Selecting putative SRY and/or SOX3 target genes in mouse dataset {#ajmgb32704-sec-0016}
---------------------------------------------------------------------

Datasets from ChIP‐chip SRY (Li et al., [2014](#ajmgb32704-bib-0070){ref-type="ref"}) and ChIP‐seq SOX3 (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}) from mice resulted in 3,738 and 7,610 targeted genes, respectively, with an overlap of 1,253 genes. Thus, we analyzed three datasets: SRY‐exclusive (2,485 genes), SOX3‐exclusive (6,357 genes) and SRY/SOX3 dataset (1,253 genes; Table [1](#ajmgb32704-tbl-0001){ref-type="table"}, Figure [1](#ajmgb32704-fig-0001){ref-type="fig"}a). A detailed flowchart with all steps involved in these analyses is available in the Supporting Information ([Figure S1](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}).

###### 

Mouse genes target by SOX3 and SRY

  Protein                                         Method      Tissue or cell                    Number of peaks   Closest RefSeq annoation                                             Entrez gene   Total genes   References
  ----------------------------------------------- ----------- --------------------------------- ----------------- -------------------------------------------------------------------- ------------- ------------- ------------------------------------------------------------------
  SRY[a](#ajmgb32704-note-0001){ref-type="fn"}    ChIP‐chip   Gonad cells from embrionic 13.5   3,083             5,704                                                                3,738         3,738         Li et al. ([2014](#ajmgb32704-bib-0070){ref-type="ref"})
  SOX3[b](#ajmgb32704-note-0002){ref-type="fn"}   ChIP‐seq    ES cells (E14.1)                  9,719             7,984                                                                5,307         7,610         (Bergsland et al. ([2011](#ajmgb32704-bib-0010){ref-type="ref"})
  NPCs cells from ES cell monolayer               8,067       7,523                             5,150             McAninch and Thomas ([2014](#ajmgb32704-bib-0077){ref-type="ref"})                               

ChIP‐chip background (27,530 RefSeq and 18,878 entrez gene).

Mouse background UCSC mm9 (34,917 RefSeq and 24,467 entrezgene).

![Overview of the analysis in mouse model. (a) Briefly, analysis from SOX3 ChIP‐seq (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}) and SRY ChIP‐chip (Li et al., [2014](#ajmgb32704-bib-0070){ref-type="ref"}) to identify target genes regulated by both protein. Genes were filtered out, according to brain tissue expression (Sharma et al., [2015](#ajmgb32704-bib-0114){ref-type="ref"}; Thompson et al., [2014](#ajmgb32704-bib-0121){ref-type="ref"}), resulting in 4,466 SOX3 target genes, 1,838 SRY target genes and 1,074 SOX3/SRY target genes. (b) To investigate whether these datasets related to brain, enrichment analysis was performed in several databases, with the respective number of genes shown in the rows using MSET (Eisinger et al., [2013](#ajmgb32704-bib-0037){ref-type="ref"}), with 10,000 permutations and FDR correction. The color scale represents −log10(FDR). (c) GO analysis (left panel) and phenotype (right panel) analysis was performed using Webgestalt (Wang et al., [2013](#ajmgb32704-bib-0132){ref-type="ref"}) and was considered to be relevant those categories with at least 10 genes and *p* value adjusted by the Benjamini--Hochberg *p* value \<0.05, represented by a word cloud. This last analysis revealed several phenotypes relevant to ASD. The phenotypes related to abnormal nervous development, growth and size, craniofacial abnormalities, behavior and neurological phenotype, mortality during fetal or postnatal period, normal phenotype, vision/eye phenotype, and abnormal oxygen level \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g001){#ajmgb32704-fig-0001}

3.2. Selecting putative SRY and/or SOX3 target genes during brain development {#ajmgb32704-sec-0017}
-----------------------------------------------------------------------------

To maximize the probability of studying only those genes related to brain development, SRY and SOX3 target genes were selected from expression databases of prenatal and postnatal periods of brain development (Thompson et al., [2014](#ajmgb32704-bib-0121){ref-type="ref"}) and specific cell types (microglia, astrocytes, oligodendrocytes and cortical neurons; Sharma et al., [2015](#ajmgb32704-bib-0114){ref-type="ref"}). From 10,095 genes, 7,378 (73%) were expressed in at least one brain sample. From this number, 4,466 represented 70% of all targeted by SOX3, 1,838 (74%) by SRY, and 1,074 (86%) by both SOX3 and SRY (SOX3/SRY; Supporting Information Table [S2](#ajmgb32704-supitem-0003){ref-type="supplementary-material"}). As the data from ChIP‐chip SRY (Li et al., [2014](#ajmgb32704-bib-0070){ref-type="ref"}) came from embryonic gonadal cells and not NPCs as the SOX3, we also performed an enrichment analysis with tissue specific pattern of large scale RNA‐seq datasets from 13 tissues (Lin et al., [2014](#ajmgb32704-bib-0071){ref-type="ref"}), using brain and testis genes. The analysis showed that for the SOX3/SRY set, only the brain tissue‐specific dataset was overrepresented, with 15 genes (9.26%, FDR \[false discovery rate\] = 3.70E−02, FE \[Fold Enrichment\] = 1.79); the testis tissue‐specific had an overlap of one gene (0.02%, FDR = 1, FE = 0.055). Similar results were observed for the SOX3 exclusive gene set with 54 genes (33.33%, FDR = 2.00E−04, FE = 1.83) for the brain and 26 genes (6%, FDR = 1, FE = 0.337) for the testes. No enrichment was observed for SRY exclusive gene sets (Supporting Information Table [S3](#ajmgb32704-supitem-0004){ref-type="supplementary-material"}).

3.3. Were putative SRY and/or SOX3 targets enriched in the genes with nervous system cell‐specific expression patterns? {#ajmgb32704-sec-0018}
-----------------------------------------------------------------------------------------------------------------------

We evaluated the expression levels in brain cell types. Cell specific expression patterns were defined by Shannon entropy (Schug et al., [2005](#ajmgb32704-bib-0112){ref-type="ref"}), using a dataset of 19,501 transcripts expressed in astrocytes, oligodendrocytes, adult microglia and cortical neurons (Sharma et al., [2015](#ajmgb32704-bib-0114){ref-type="ref"}). Only transcripts that reported entropy (H) below or equal to two were selected. Each transcript was then assigned to the tissue that had the lowest Q value, identifying those transcripts preferentially expressed in a cell type but not exclusively expressed in a specific cell type (Supporting Information Figure [S2](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}).

Comparing the cell‐specific expression to the SOX3/SRY dataset, there were an overrepresentation in two groups of cortical neurons (division 05: FDR = 7.00E−04, FE = 2.69 and division 10: FDR = 8.80E−03, FE = 1.54). For the SRY exclusive target genes, adult microglia FDR = 2.00E−04, FE = 1.68), cortical neurons (division 10: FDR = 2.00E−04, FE = 1.59) and astrocytes (FDR = 2.00E−04, FE = 1.47) were overrepresented. For the SOX3 exclusive target genes, overrepresentation was found for the cortical neurons (division 05: FDR = 2.00E−04, FE = 1.99 and division 10: FDR = 1.00E−04, FE = 1.64), oligodendrocytes (division 2.5: FDR = 1.80E−03, FE = 1.7 and division 4: FDR = 1.37E−02, FE = 1.51) and astrocytes (FDR = 2.00E−04, FE = 1.47; Figure [1](#ajmgb32704-fig-0001){ref-type="fig"}b, Supporting Information Table [S4](#ajmgb32704-supitem-0005){ref-type="supplementary-material"}).

3.4. Were putative SOX3 and/or SRY targets enriched for biological processes related to neurodevelopment? {#ajmgb32704-sec-0019}
---------------------------------------------------------------------------------------------------------

To investigate the biological function of the SOX3/SRY dataset, we performed an enrichment analysis within the biological processes from gene ontology, which revealed several categories related to brain development, including dendrite development (30 genes, R = 2.41, adjP = 1.42E−03), neuron migration (23 genes, R = 2.5, adjP = 2.86E−03), axon development (48 genes, R = 1.77, adjP = 4.10E−03) and synapse organization (29 genes, R = 1.89, adjP = 1.90E−02). The other categories were skeletal system development (52 genes, R = 1.79, adjP = 2.47E−03), cell--cell signaling by wnt (40 genes, R = 1.73, adjP = 1.55E−02) and embryonic organ development (46 genes, R = 1.58, adjP = 2.53E−02; Supporting Information Table [S5](#ajmgb32704-supitem-0006){ref-type="supplementary-material"}). While enrichment analysis from SOX3 dataset was similar to the one from the SOX3/SRY dataset (Supporting Information Table [S6](#ajmgb32704-supitem-0007){ref-type="supplementary-material"}), the SRY dataset showed only the cell‐substrate junction category (64 genes, R = 1.53, adjP = 4.49E−02) enriched.

Moreover, the SOX3/SRY dataset phenotype analysis showed enrichment for abnormal nervous system physiology (162 genes, R = 1.63E−05, adjP = 1.63E−05), abnormal brain development (70 genes, R = 1.77, adjP = 1.77E−03), abnormal synaptic transmission (72 genes, R = 1.79, adjP = 1.16E−03), abnormal axon extension (12 genes, R = 3.15, adjP = 3.69E−02), abnormal neuronal migration (16 genes, R = 2.62, adjP = 3.69E−02) and craniofacial phenotype (92 genes, R = 1.41, adjP = 3.69E−02). Phenotypes related to behavior were also identified in the abnormal cued conditioning behavior (19 genes, R = 3.01, adjP = 6.22E−03) and abnormal emotion/affect behavior (58 genes, R = 1.69, adjP = 1.15E−02) categories (Supporting Information Table [S7](#ajmgb32704-supitem-0008){ref-type="supplementary-material"}, Figure [1](#ajmgb32704-fig-0001){ref-type="fig"}c).

3.5. Identification of putative human SRY and/or SOX3 target genes {#ajmgb32704-sec-0020}
------------------------------------------------------------------

To investigate these findings in a human model, we identified orthologous genes between the mouse and human genome and improved our original dataset with additional datasets of SRY ChIP‐chip assays in humans and rats (Supporting Information Table [S8](#ajmgb32704-supitem-0009){ref-type="supplementary-material"}). We verified that SRY and SOX3 are conserved among species by aligning the SOX3 HMG‐box domains from mice and humans, showing that both domains were identical. SRY was highly conserved among species, with 54 identical residues (78%) and four similar residues (6%; Figure [2](#ajmgb32704-fig-0002){ref-type="fig"}a, Supporting Information Figure [S3](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}).

![Summary of designed experiments in human model. (a) Chromatin immunoprecipitation of SOX3 and SRY from mouse, human, and rat models were selected in the literature. First, HMG‐box DNA binding motif sequence conservation was evaluated among the species; after confirming it, human orthologues genes were identified. (b) SOX3 and SRY targets (first Venn diagram) were filtered for brain expression (second Venn diagram), then three main experiments were performed: one regarding ASD databases (purple box), other brain development (lilac box) and, the last regarding differential sex modulation (pink box). (c) Preservation module coexpression analysis of 1,721 SOX3/SRY set comparing ASD and CON showed that least preserved modules brown and red were primarily related to the stress response and neurogenesis, respectively \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g002){#ajmgb32704-fig-0002}

The identification of orthologous genes between species showed 4,297 unique genes with SRY binding sites (Bhandari et al., [2012](#ajmgb32704-bib-0012){ref-type="ref"}; Jin et al., [2007](#ajmgb32704-bib-0053){ref-type="ref"}; Li et al., [2014](#ajmgb32704-bib-0070){ref-type="ref"}) and 7,221 unique genes with SOX3 binding sites (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}) for humans. From these genes, 3,798 (88%) SRY and 6,415 (89%) and SOX3 target genes, respectively, were expressed during brain development (Figure [2](#ajmgb32704-fig-0002){ref-type="fig"}b, Supporting Information Table [S9](#ajmgb32704-supitem-0010){ref-type="supplementary-material"}). There was an overlap of 1,721 genes between SOX3 and SRY (SOX3/SRY set), and 2,077 and 4,694 genes were targeted exclusively by SRY (SRY set) and SOX3 (SOX3 set), respectively. From the SOX3/SRY set, 19 genes are located in the X chromosome (1%); from the SRY set, 73 and 2 genes are located on the X (3.5%) and Y (0.1%) chromosomes; and from the SOX3 set, 122 (2.6%) and three (0.06%) genes are located on X and Y chromosomes, respectively.

As the DNA binding domains from both proteins were conserved, we searched for evidence of whether the three gene sets had the same regulatory modulation mechanism among the species. We used the poised H3K4me3/H3K27me3 bivalent epigenetic state in male germ cells from five mammalian species; this state is closely related to the gene regulatory programs that govern somatic development (Lesch, Silber, McCarrey, & Page, [2016](#ajmgb32704-bib-0068){ref-type="ref"}). Poised genes are those that present H3K4me3 and H3K27me3 marks in a window of 4 kb from TSS (≥0.5 reads per million) and expression ≤5 FPKM. This definition identified 405 poised promoter genes among the species and 1,929 between the mice and humans (Lesch et al., [2016](#ajmgb32704-bib-0068){ref-type="ref"}).

Thus, we sought to analyze the SOX3/SRY set independently of the species by performing an enrichment analysis to identify which genes from the SRY/SOX3 set maintain marks that are conserved across species. This analysis showed that the SOX3/SRY set was overrepresented in 78 (19%, FDR = 1.00E−04, FE = 2.31) genes conserved across five species and 310 (16%, FDR = 1.00E−04, FE = 1.93) genes conserved between mice and humans. Similar enrichment results were observed for the SOX3 set. However, only the poised promoters conserved in mouse and human were enriched for the SRY set (Supporting Information Table [S10](#ajmgb32704-supitem-0011){ref-type="supplementary-material"} and Figure [S4](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}).

Functional annotation analyses of the SOX3/SRY set identified overrepresentation for the immune system, metabolism, nervous system development, and gene expression and nervous system component regulation, such as synapses, axons and the neuronal spine (Table [2](#ajmgb32704-tbl-0002){ref-type="table"} and Supporting Information Tables [S11](#ajmgb32704-supitem-0012){ref-type="supplementary-material"} and [S12](#ajmgb32704-supitem-0013){ref-type="supplementary-material"}). Similar results were observed for the SOX3 exclusive gene set (Supporting Information Table [S13](#ajmgb32704-supitem-0014){ref-type="supplementary-material"}), and no enrichment was found for the SRY exclusive gene set. A summary of the designed experiments is shown in Figure [2](#ajmgb32704-fig-0002){ref-type="fig"}, and a detailed flowchart of the analyses is available in the Supporting Information (Figure [S5](#ajmgb32704-supitem-0006){ref-type="supplementary-material"}).

###### 

Functional categories enriched according to 1,721 SOX3/SRY target genes expressed in brain

  GO type                             GO ID                                  GO category name                                            C        O       E        R          *p*
  ----------------------------------- -------------------------------------- ----------------------------------------------------------- -------- ------- -------- ---------- ----------
  Gene ontology enrichment analysis                                                                                                                                           
  BP                                  GO:0007399                             Nervous system development                                  1,724    298     174.17   1.71       1.19E−19
  BP                                  GO:0010468                             Regulation of gene expression                               3,344    492     337.83   1.46       1.79E−19
  BP                                  GO:0060255                             Regulation of macromolecule metabolic process               4,151    581     419.36   1.39       2.33E−19
  BP                                  GO:0022008                             Neurogenesis                                                1,140    218     115.17   1.89       2.33E−19
  BP                                  GO:0048699                             Generation of neurons                                       1,073    209     108.4    1.93       2.33E−19
  BP                                  GO:0006351                             Transcription, DNA‐dependent                                3,220    470     325.3    1.44       2.95E−18
  BP                                  GO:0045595                             Regulation of cell differentiation                          1,012    196     102.24   1.92       2.95E−18
  BP                                  GO:0031326                             Regulation of cellular biosynthetic process                 3,325    482     335.91   1.43       2.95E−18
  BP                                  GO:0006355                             Regulation of transcription, DNA‐dependent                  2,876    430     290.55   1.48       2.95E−18
  BP                                  GO:2000112                             Regulation of cellular macromolecule biosynthetic process   3,119    458     315.1    1.45       3.08E−18
  BP                                  GO:2001141                             Regulation of RNA biosynthetic process                      2,897    432     292.67   1.48       3.20E−18
  BP                                  GO:0048646                             Anatomical structure formation involved in morphogenesis    1,594    273     161.03   1.7        3.29E−18
  BP                                  GO:0030182                             Neuron differentiation                                      990      192     100.02   1.92       4.91E−18
  BP                                  GO:0048468                             Cell development                                            1,461    255     147.6    1.73       5.24E−18
  MF                                  GO:0044212                             Transcription regulatory region DNA binding                 328      73      31.33    2.33       1.10E−10
  MF                                  GO:0001067                             Regulatory region nucleic acid binding                      336      74      32.1     2.31       1.10E−10
  MF                                  GO:0005488                             Binding                                                     11,955   1,239   1,142    1.08       2.68E−10
  CC                                  GO:0000785                             Chromatin                                                   296      62      27.48    2.26       1.80E−08
  CC                                  GO:0045202                             Synapse                                                     489      79      45.39    1.74       6.84E−06
  CC                                  GO:0030425                             Dendrite                                                    355      57      32.95    1.73       2.00E−04
  CC                                  GO:0031252                             Cell leading edge                                           257      44      23.86    1.84       3.00E−04
  CC                                  GO:0030424                             Axon                                                        286      47      26.55    1.77       5.00E−04
  CC                                  GO:0044309                             Neuron spine                                                159      30      14.76    2.03       6.00E−04
  CC                                  GO:0042995                             Cell projection                                             1,230    152     114.18   1.33       6.00E−04
  CC                                  GO:0043197                             Dendritic spine                                             159      30      14.76    2.03       6.00E−04
  CC                                  GO:0016607                             Nuclear speck                                               148      28      13.74    2.04       1.20E−03
  CC                                  GO:0044456                             Synapse part                                                370      54      34.35    1.57       3.40E−03
  CC                                  GO:0097060                             Synaptic membrane                                           215      35      19.96    1.75       3.70E−03
  CC                                  GO:0030027                             Lamellipodium                                               121      23      11.23    2.05       3.70E−03
  CC                                  GO:0014069                             Postsynaptic density                                        116      22      10.77    2.04       4.60E−03
  CC                                  GO:0044327                             Dendritic spine head                                        116      22      10.77    2.04       4.60E−03
  KEGG pathway analysis                                                                                                                                                       
  KEGG                                Systemic lupus erythematosus           136                                                         40       5.43    7.37     5.41E−22   
  KEGG                                Pathways in cancer                     326                                                         54       13.01   4.15     2.50E−17   
  KEGG                                Wnt signaling pathway                  150                                                         35       5.99    5.85     3.99E−16   
  KEGG                                MAPK signaling pathway                 268                                                         42       10.69   3.93     6.74E−13   
  KEGG                                Focal adhesion                         200                                                         32       7.98    4.01     3.23E−10   
  KEGG                                Neurotrophin signaling pathway         127                                                         23       5.07    4.54     1.21E−08   
  KEGG                                Calcium signaling pathway              177                                                         27       7.06    3.82     1.87E−08   
  KEGG                                Regulation of actin cytoskeleton       213                                                         30       8.5     3.53     1.87E−08   
  KEGG                                Axon guidance                          129                                                         22       5.15    4.27     5.59E−08   
  KEGG                                Metabolic pathways                     1,130                                                       75       45.09   1.66     3.58E−05   
  KEGG                                Leukocyte transendothelial migration   116                                                         16       4.63    3.46     3.74E−05   
  KEGG                                Viral myocarditis                      70                                                          12       2.79    4.3      4.27E−05   

Abbreviations. BP = biological process; C = number of reference genes in the category; CC = cellular component; E = expected number in the category; MC = molecular component; O = number of genes in the gene set and also in the category; *p* = *p* value adjusted by multiple test adjustment (FDR); R = ratio of enrichment.

3.6. Do putative SRY and/or SOX3 target genes have male‐biased expression, and were and were they specifically modulated during brain development? {#ajmgb32704-sec-0021}
--------------------------------------------------------------------------------------------------------------------------------------------------

Using MSIgDB/WebGestalt, we found that genes from the SOX3/SRY set were overrepresented in several TFs, including sex hormone receptors (Supporting Information Table [S14](#ajmgb32704-supitem-0015){ref-type="supplementary-material"}). Thus, a set of genes were directly regulated by androgens (AR, 65 genes, 3%, *p* \< 1E−05) and estrogen (ER, 112 genes, 6.5%, p \< 1E−10); this set of genes totaled 167 genes that are directly targeted by AR and/or ER (i.e., 9.8%; Supporting Information Table [S15](#ajmgb32704-supitem-0016){ref-type="supplementary-material"}).

To determine the involvement of the SRY/SOX3 set in neurodevelopment, we used modules of genes coexpressed during neocortical development (Parikshak et al., [2013](#ajmgb32704-bib-0089){ref-type="ref"}). We identified nine enriched modules, one of which showed enrichment for ER targets (Table [3](#ajmgb32704-tbl-0003){ref-type="table"} and Figure [3](#ajmgb32704-fig-0003){ref-type="fig"}). Thus, AR (*n* = 65) and ER (*n* = 112) target genes were tested as two independent datasets. Comparing both analyses, eight modules were enriched only in the SOX3/SRY set, four (M3, M5, M11 and M14) were all composed of genes that have their highest expression levels during the early (8--12 postconception week, PCW) period and one (M2) during the mid‐fetal period (13--17 PCW). These genes were involved with biological processes that are primarily related to zinc ion binding, nucleic acid metabolic process, translational elongation and viral transcription (Supporting Information Table [S16](#ajmgb32704-supitem-0017){ref-type="supplementary-material"}). The other three modules (M1, M16 and M18) demonstrated higher expression levels in the postbirth period, with M1 and M18 showing expression in the early periods of gestation. Only the M8 module was enriched for the SOX3/SRY set and ER, and it was composed of genes that have their highest expression levels during the early fetal period (8--12 PCW; Supporting Information Figure [S6](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}).

###### 

Enrichment analysis of specific neurodevelopmental modules

  Modules[a](#ajmgb32704-note-0006){ref-type="fn"}   SOX3/SRY BRAIN   SOX3    SRY            AR             ER                                                                                                                                                          
  -------------------------------------------------- ---------------- ------- -------------- -------------- ----- ------- -------------- -------------- ----- ------- -------------- -------------- --- ------- -------------- ---------- --- ---------- -------------- --------------
  M1                                                 75               1.47    **8.00E−04**   **2.72E−03**   217   1.58    **1.00E−04**   **2.43E−04**   56    0.952   6.77E−01       7.67E−01       5   2.59    **4.61E−02**   3.92E−01   2   6.00E−01   8.55E−01       1.00E+00
  M2                                                 78               1.29    **1.15E−02**   **2.79E−02**   217   1.33    **1.00E−04**   **2.43E−04**   78    1.16    9.27E−02       1.58E−01       2   0.876   6.75E−01       1.00E+00   4   1.02E+00   5.56E−01       1.00E+00
  M3                                                 115              1.66    **1.00E−04**   **5.67E−04**   274   1.41    **1.00E−04**   **2.43E−04**   104   1.3     **3.10E−03**   **8.78E−03**   1   0.383   9.27E−01       1.00E+00   4   8.90E−01   6.69E−01       1.00E+00
  M4                                                 30               1.02    4.71E−01       6.16E−01       94    1.27    **6.10E−03**   **9.43E−03**   55    1.72    **1.00E−04**   **5.67E−04**   0   0       1.00E+00       1.00E+00   0   0.00E+00   1.00E+00       1.00E+00
  M5                                                 80               1.33    **4.90E−03**   **1.39E−02**   239   1.49    **1.00E−04**   **2.43E−04**   80    1.15    1.05E−01       1.62E−01       5   2.2     7.38E−02       4.18E−01   2   5.11E−01   9.06E−01       1.00E+00
  M6                                                 18               0.697   9.64E−01       1.00E+00       70    1.01    4.81E−01       6.29E−01       31    1.07    3.75E−01       4.55E−01       0   0       1.00E+00       1.00E+00   0   0.00E+00   1.00E+00       1.00E+00
  M8                                                 33               2       **1.00E−04**   **5.67E−04**   66    1.46    **3.00E−04**   **6.38E−04**   29    1.49    **1.98E−02**   **4.81E−02**   0   0       1.00E+00       1.00E+00   6   5.60E+00   **7.00E−04**   **1.19E−02**
  M9                                                 17               0.963   5.98E−01       7.26E−01       42    0.894   8.16E−01       9.79E−01       18    0.888   7.37E−01       7.83E−01       1   1.5     4.77E−01       1.00E+00   0   0.00E+00   1.00E+00       1.00E+00
  M10                                                2                0.789   7.26E−01       8.23E−01       4     0.617   9.21E−01       9.79E−01       1     0.35    9.48E−01       9.48E−01       0   0       1.00E+00       1.00E+00   0   0.00E+00   1.00E+00       1.00E+00
  M11                                                63               1.59    **1.00E−04**   **5.67E−04**   134   1.25    **1.90E−03**   **3.23E−03**   53    1.17    1.25E−01       1.77E−01       0   0       1.00E+00       1.00E+00   6   2.33E+00   **4.91E−02**   2.09E−01
  M12                                                11               0.366   1.00E+00       1.00E+00       46    0.57    1.00E+00       1.00E+00       57    1.78    **1.00E−04**   **5.67E−04**   1   0.881   6.79E−01       1.00E+00   0   0.00E+00   1.00E+00       1.00E+00
  M13                                                67               1.12    1.75E−01       2.98E−01       199   1.26    **1.00E−04**   **2.43E−04**   98    1.44    **1.00E−04**   **5.67E−04**   2   0.884   6.68E−01       1.00E+00   3   1.28E+00   3.54E−01       1.00E+00
  M14                                                53               1.34    **2.01E−02**   **4.27E−02**   106   0.912   8.73E−01       9.79E−01       73    1.63    **1.00E−03**   **3.40E−03**   1   0.64    7.77E−01       1.00E+00   1   3.89E−01   9.26E−01       1.00E+00
  M15                                                28               1.12    2.96E−01       4.19E−01       79    1.15    9.10E−02       1.29E−01       38    1.34    **3.99E−02**   8.48E−02       1   1.06    6.14E−01       1.00E+00   4   2.45E+00   8.61E−02       2.93E−01
  M16                                                50               1.32    **2.28E−02**   **4.31E−02**   137   1.34    **1.00E−04**   **2.43E−04**   53    1.21    8.14E−02       1.54E−01       5   3.51    **1.30E−02**   2.21E−01   6   2.44E+00   **3.94E−02**   2.09E−01
  M17                                                73               1.09    2.44E−01       3.77E−01       248   1.39    **1.00E−04**   **2.43E−04**   86    1.12    1.39E−01       1.82E−01       2   0.79    7.21E−01       1.00E+00   5   1.15E+00   4.41E−01       1.00E+00
  M18                                                89               1.43    **4.00E−04**   **1.70E−03**   202   1.2     **1.50E−03**   **2.83E−03**   102   1.38    **6.00E−04**   **2.55E−03**   1   0.424   9.13E−01       1.00E+00   9   2.22E+00   **2.04E−02**   1.73E−01

\#: Number of overlapping genes. FE = fold enrichment.

Bold: *p* value (10,000 permutations) or FDR ≤ 0.05.

Results from Parikshak et al. ([2013](#ajmgb32704-bib-0089){ref-type="ref"}).

![Enrichment analysis in neurodevelopment modules: Each line represents a gene set with the respective number of genes or a gestation period and each column is represented by neurodevelopmental gene modules with respective number of genes (Parikshak et al., [2013](#ajmgb32704-bib-0089){ref-type="ref"}), totaling 17 modules. The circles are proportional with gene overlap in each dataset, and the numbers represent the number of overlapping genes. Colors are proportional to significant enrichment, those scaled in red were those that reached the threshold of FDR \< 0.05 \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g003){#ajmgb32704-fig-0003}

In the SOX3 set, a total of 11 modules were enriched. Three new modules were enriched (M4, M13 and M17), while the other eight modules were also enriched for the SOX3/SRY set. The expression level of the M17 module increases throughout the gestational period, stabilizing after birth. The M4 and M13 modules were also shared with the SRY set, with both modules having their highest expression levels after birth. Regarding the SRY set, a total of seven modules were enriched. As stated above, two modules are shared with the SOX3 set, and four are also present in the SOX3/SRY gene set (M3, M8, M14 and M18), all showing the highest expression level in the first periods of gestation, with M18 also peaking after birth; one module (M12) is exclusive to this set. The highest expression level of the M12 module was during the mid‐fetal period, and its biological processes are primarily related to cilium, cell projection and axoneme. Most enriched modules that are exclusive to the SOX3 and SRY sets are characterized by having their highest expression levels after birth. These modules were related to synapses signaling, ion channel transmembrane and oxidative phosphorylation (Supporting Information Table [S16](#ajmgb32704-supitem-0017){ref-type="supplementary-material"}).

We also compared the SOX3/SRY set to 37 females and 123 males genes that showed sex biased expression during brain development (Kang et al., [2011](#ajmgb32704-bib-0056){ref-type="ref"}). There was no overlap between the female‐biased gene set and the SOX3/SRY set. However, the male‐biased gene set was enriched in the SOX3/SRY set (19.5%, 24/123, *p* \< 1E−04, 10,000 pe, FE = 2.37; Figure [4](#ajmgb32704-fig-0004){ref-type="fig"}a). The genes potentially regulated by AR and/or ER and that are part of the SOX3/SRY set were not enriched for either set, with only two overlapping genes (*ZIC1* ‐ targeted by ER and *ZNF423* targeted by AR). Using the SOX3 or SRY set, no enrichment was observed in the female or male biased expression.

![Enrichment analysis using MSET (Eisinger et al., [2013](#ajmgb32704-bib-0037){ref-type="ref"}) (a) Dataset of 389 unique autosomal genes that were differentially methylated between 100 males and 79 females fetal brain samples, aged 23--184 days postconception (Spiers et al., [2015](#ajmgb32704-bib-0116){ref-type="ref"}) (b) A dataset of 159 genes that were differentially expressed between 31 males and 26 females from brain samples aged 5.7 postconception weeks to 82 years (Kang et al., [2011](#ajmgb32704-bib-0056){ref-type="ref"}). In both graphics, the x‐axis indicates the number of overlapping genes between datasets (Amethylation and B‐expression vs. 1,721 SOX3/SRY/brain target genes), and the y‐axis indicates the proportion of this overlap according to the number of permutations (*n* = 10,000). The blue line indicates the number of overlapping genes, with 1,721 target genes of SOX3/SRY, and the histogram shows the probability of density, according to the simulations. The methylation dataset had 40 genes (10%, *p* value = 0.0466), and the expression dataset had 24 genes (19.5%, *p* value \<0.0001). (c) A Venn diagram of the SOX3/SRY target genes expressed in the brain (*n* = 1,721, green circle), showing the differentially methylated dataset (*n* = 389 autosomal genes, blue circle) and the male‐bias expression dataset (*n* = 123 genes, red circle). The size of the circle is proportional to the total number of genes. The gene in the overlapping region is COX7A2. (d) SRY and SOX3‐network. Networks of each protein SOX3 (left) and SRY (right) are shown. The heatmap shows 18 transcription factors (rows) found in the enrichment analysis of 1,721 SOX3/SRY and related functions in the columns. Yellow and black indicate the presence and absence, respectively. Four are in SOX3‐network related to brain development(red blocks), and 14 TFs are in SRYnetwork (gray blocks) and are related to sex determination, cell cycle, cardiovascular, and other function as histone regulation, brain development and immune system \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g004){#ajmgb32704-fig-0004}

3.7. Do putative SRY and/or SOX3 target genes show different methylation target sites between males and females during brain development? {#ajmgb32704-sec-0022}
-----------------------------------------------------------------------------------------------------------------------------------------

We compared the SOX3/SRY, SOX3 and SRY sets to 389 unique autosomal genes that were differentially methylated between males and females during brain development (Spiers et al., [2015](#ajmgb32704-bib-0116){ref-type="ref"}). No enrichment was observed in the SOX3 set, while the SRY set identified 52 genes (*p* = .0068, 10,000 pe, FE = 1.41) represented by 57 CpGs sites, with 32 sites more methylated in males and 25 in females. Using the SOX3/SRY set, we found an overlap of 40 genes (10%, 40/389, *p* = 4.66E−02, 10,000 pe, FE = 1.31) represented by 45 CpG sites, with 19 sites more methylated in males and 26 in females (Figure [4](#ajmgb32704-fig-0004){ref-type="fig"}b, Supporting Information Table [S17](#ajmgb32704-supitem-0018){ref-type="supplementary-material"}). Moreover, the genes regulated by AR and/or ER within the SOX3/SRY set were not enriched within the 389 genes, with only *HOXC4*, *SGK1*, *SPTBN1*, *TOMM40*, *CHD6* and *ZNF503* appearing in both lists. From the 45 differentially methylated CpG sites between sexes, twenty‐seven (60%, 26 genes) were located at precisely the same genomic coordinates of the SRY peaks, including all 19 CpGs more methylated in males. Only four CpG sites (4 genes, 9%) overlapped SOX3 peaks. We found that the SOX3 peaks (\~ 328 bp) were smaller than the SRY peaks (\~1,879 bp) and that they were distributed farther than 3 kb upstream or downstream from the methylated CpG sites (Supporting Information Figure [S7](#ajmgb32704-supitem-0001){ref-type="supplementary-material"} and Table [S18](#ajmgb32704-supitem-0019){ref-type="supplementary-material"}).

*COX7A2* is one of the genes in the overlap list (Figure [4](#ajmgb32704-fig-0004){ref-type="fig"}c, Supporting Information Figure [S8](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}). It is hypomethylated and more expressed in males during brain development, with its CpG sites located within SRY and SOX3 peaks with histone marks (H3K4me3). These histone marks are regulatory marks of active promoter regions (Barski et al., [2007](#ajmgb32704-bib-0008){ref-type="ref"}; Kimura, [2013](#ajmgb32704-bib-0058){ref-type="ref"}), indicating that both proteins may be involved in the regulation of this region.

The different roles of SRY and SOX3 could be related to their protein partners. Using STRING (Szklarczyk et al., [2017](#ajmgb32704-bib-0119){ref-type="ref"}), two networks were built using the same parameters. The SRY‐network comprised 101 genes with 649 edges (average \[avg\] node degree 12.9 and avg. local clustering coefficient of 0.736), whereas the SOX3‐network comprised 47 genes and 223 edges (avg node degree 9.49 and avg local clustering coefficient of 0.79). The two networks only share ten genes (i.e., *CTNNB1*, *HERC5*, *HERC6*, *HERC1*, *HERC3*, *BRD2*, *HERC2*, *HERC4*, *DMRT1*, *SHOX*). When we investigated only the TFs in each network, SRY and SOX3 showed 41 (41%) and 22 genes (47%), respectively, with five common TFs (*CTNNB1*, *HERC1*, *BRD2*, *DMRT1*, and *SHOX*). A previous enrichment analysis identified 18 TFs (Table [4](#ajmgb32704-tbl-0004){ref-type="table"}, Supporting Information Table [S14](#ajmgb32704-supitem-0015){ref-type="supplementary-material"}), with four in the SOX3‐network targeting 233 SOX3/SRY genes and 14 TFs in the SRY‐network targeting 821 SOX3/SRY genes. The four TFs from the SOX3‐network (*MEIS1*, *PAX6*, *POU1F1*, and *LHX3*) have known roles in neurodevelopment, particularly pituitary gland and eye development. The TFs inform that SRY‐network plays a broader role, such as sex determination, cell cycle and differentiation, immune system, and neural development (Figure [4](#ajmgb32704-fig-0004){ref-type="fig"}d).

###### 

Transcription factor in SOX3 and SRY networks (STRING)

  Entrez gene   STRING ID   SOX3   SRY   Unirprot_Human                   Family                   TF enrichment                                                                  Related function (NCBI, RefSeq)
  ------------- ----------- ------ ----- -------------------------------- ------------------------ ------------------------------------------------------------------------------ --------------------------------------------------------------------------------
  367           AR          N      Y     F1D8N5,P10275                    Androgen receptor        hsa_V\$AR_01, hsa_V\$AR_Q2, hsa\$AR_Q6                                         Steroid‐hormone activated transcription factor, sex determination related gene
  1482          NKX2‐5      N      Y     P52952                           Homeobox                 hsa_V\$NKX25_01, hsa_V\$NKX25_2                                                Heart formation and development
  2033          EP300       N      Y     Q09472, Q7Z6C1                   NA                       hsa_V\$P300_01                                                                 Chromatin remodeling, histone acetyltransferase
  2099          ESR1        N      Y     A8KAF4, G4XH65, P03372, Q9UBT1   Oestrogen receptor       hsa_V\$ER_Q6, hsa_V\$ER_Q6_01, hsa_V\$ER_Q6_02                                 Hormone binding, sex development
  2516          NR5A1       N      Y     F1D8R8, Q13285                   Retinoic acid receptor   hsa_TGACCTTG_V\$SF1_Q6, hsa_V\$SF1_Q6                                          Sex determination related gene
  2626          GATA4       N      Y     B3KUF4, P43694                   Zf‐GATA                  hsa_V\$GATA4_Q3                                                                Embryogenesis, testicular differentiation, cardiovascular
  4088          SMAD3       N      Y     P84022, Q9P0T0                   MH1                      hsa_V\$SMAD3_Q6                                                                Cell cycle
  4211          MEIS1       Y      N     F5GYS8, O00470                   Homeobox                 hsa_TGACAGNY_V\$MEIS1_01, hsa_V\$MEIS1_01, hsa_V\$MEIS1AHOXA9_01               Crucial for normal development
  4609          MYC         N      Y     P01106                           bHLH                     hsa_V\$MYCMAX_01, hsa_V\$MYCMAX_02, has_V\$MYCMAX_03                           Cell cycle
  5080          PAX6        Y      N     F1T0F8, P26367, Q66SS1           PAX                      hsa_V\$PAX6_01                                                                 Neural development, particularly eye
  5449          POU1F1      Y      N     P28069                           POU                      hsa_V\$POU1F1_Q6                                                               Brain and pituitary development
  6667          SP1         N      Y     P08047                           zf‐C2H2                  hsa_GGGCGGR_V\$SP1_Q6, hsa_V\$SP1_Q6, hsa_V\$SP1_Q6_01                         Cell cycle
  6736          SRY         N      Y     A7WPU8, Q05066                   HMG                      hsa_V\$SRY_01, hsa_V\$SRY_02                                                   Sex determination related gene
  6925          TCF4        N      Y     B3KVA4, H3BTP3, P15884           bHLH                     hsa_V\$TAL1BETAITF2_01                                                         Nervous system development
  7157          TP53        N      Y     H2EHT1, K7PPA8, P04637, Q53GA5   P53                      hsa_V\$P53_02                                                                  Cell cycle
  8022          LHX3        Y      N     F1T0D5, F1T0D7, F1T0D9, Q9UBR4   Homeobox                 hsa_YTAATTAA_V\$LHX3_01, hsa_V\$LHX3_01                                        Pituitary development
  27022         FOXD3       N      Y     Q9UJU5                           Fork head                hsa_V\$FOXD3_01                                                                Immune system
  51176         LEF1        N      Y     Q659G9, Q9UJU2                   HMG                      hsa_CTTTGA_V\$LEF1_Q2, hsa_CTTTGT_V\$LEF1_Q2, hsa_V\$LEF1_Q2, hsa_V\$LEF1_Q6   Cell differentiation, hair cell

3.8. Were putative SRY and/or SOX3 targets overrepresented in the ASD genes? {#ajmgb32704-sec-0023}
----------------------------------------------------------------------------

To investigate whether our gene sets could be involved in a sex‐biased neurodevelopmental disorder, we used ASD as a model and searched for their enrichment in the SFARI databases (Abrahams et al., [2013](#ajmgb32704-bib-0001){ref-type="ref"}). The SOX3/SRY and the SOX3 exclusive gene sets were enriched in the thresholds that we established for the SFARI Gene database (Table [5](#ajmgb32704-tbl-0005){ref-type="table"}, Figure [5](#ajmgb32704-fig-0005){ref-type="fig"}). We also compared these gene sets with whole exome sequencing datasets from families, using rare *de novo* variations (RDNVs; Sanders et al., [2015](#ajmgb32704-bib-0107){ref-type="ref"}), GWAS data (Autism Spectrum Disorder Working Group of the Psychiatry Genomics Consortium, [2015](#ajmgb32704-bib-0006){ref-type="ref"}) and ASD transcriptome studies (Gupta et al., [2014](#ajmgb32704-bib-0046){ref-type="ref"}; Voineagu et al., [2011](#ajmgb32704-bib-0129){ref-type="ref"}; Supporting Information Table [S19](#ajmgb32704-supitem-0020){ref-type="supplementary-material"}). These other databases used as SFARI combine both GWAS (common variants) and exome (rare variations), which have different sample power analyses. The analyses revealed that the SOX3/SRY set was enriched for all databases, except for GWAS (AUT8: 2 genes, FDR = 0.348, FE = 2.63, PGC ASD Euro: 1 gene, FDR = 0.776, FE = 0.697). Comparing all datasets to SRY or SOX3 set, only one GWAS database (PGC ASD Euro: 10 genes, FDR = 8.7E−03, FE = 2.4) was enriched for the SOX3 set, and no overrepresentation was observed in any database using SRY set. We reasoned that this result may be a consequence of the small size of these databases. However, assuming that the SOX3/SRY set represents highly conserved genes and is related to the differences between sexes in brain neurodevelopment, we expected that the data obtained from GWAS databases, which only have common variation, would not be enriched.

###### 

Autism related genes databases enrichment analysis

                                                                                                                   SOX3/SRY   SOX3   SRY                                                                                                 
  -------------------------------------------------------------------------------------------------------- ------- ---------- ------ -------------- -------------- ------- ------ -------------- -------------- ----- ------- ---------- ----------
  DDD (2017)[a](#ajmgb32704-note-0009){ref-type="fn"}                                                      93      22         2.8    **1.00E−04**   **1.50E−04**   34      1.4    **1.54E−02**   **1.54E−02**   6     0.633   9.23E−01   9.30E−01
  Sanders et al. ([2015](#ajmgb32704-bib-0107){ref-type="ref"})[b](#ajmgb32704-note-0010){ref-type="fn"}   5,413   536        1.19   **1.00E−04**   **1.50E−04**   1,593   1.17   **1.00E−04**   **2.00E−04**   573   1.05    7.87E−02   4.72E−01
  SFARI categories 1--4 (w/o syndromic genes)                                                              597     78         1.57   **1.00E−04**   **1.50E−04**   238     1.6    **1.00E−04**   **2.00E−04**   50    0.834   9.30E−01   9.30E−01
  SFARI categories 1--4 (w/ syndromic genes)                                                               665     92         1.66   **1.00E−04**   **1.50E−04**   259     1.56   **1.00E−04**   **2.00E−04**   57    0.853   9.24E−01   9.30E−01
  SFARI 1--2 (w/o syndromic genes)                                                                         56      9          1.94   **3.52E−02**   **3.52E−02**   22      1.54   **1.40E−02**   **1.54E−02**   5     0.892   6.71E−01   9.30E−01
  SFARI 1--2 (w/ syndromic genes)                                                                          84      14         2      **9.50E−03**   **1.14E−02**   31      1.43   **1.39E−02**   **1.54E−02**   8     0.946   6.13E−01   9.30E−01

\#: Number of overlapping genes, FE: Fold Enrichment.

Bold: *p* value (10,000 permutations) or FDR ≤ 0.05.

Results from Dechiphering developmental disorders (DDD; McRae et al., [2017](#ajmgb32704-bib-0080){ref-type="ref"}).

Results from Sanders et al. ([2015](#ajmgb32704-bib-0107){ref-type="ref"}).

![Enrichment analysis in ASD databases: Each line represents a gene set with the respective number of genes, and each column is represented by ASD databases with the respective number of genes. The circles are proportional with gene overlap in each dataset and the numbers represent the number of overlapping genes. Colors are proportional to significant enrichment, those scaled in red were those that reached the threshold of FDR \<0.05. \*Data from deciphering developmental disorders (DDD; McRae et al., [2017](#ajmgb32704-bib-0080){ref-type="ref"}), \*\*Data from exome study (Sanders et al., [2015](#ajmgb32704-bib-0107){ref-type="ref"}) \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g005){#ajmgb32704-fig-0005}

Then, using the database of residual variation intolerance score (RVIS; Petrovski et al., [2013](#ajmgb32704-bib-0092){ref-type="ref"}), we observed that all three gene sets (SOX3/SRY, SOX3 set, and SRY set) showed enrichment in genes that do not tolerate variations (only the SOX3/SRY set was enriched in the dataset of genes intolerant to mutations) and that are involved in early fetal brain development (15 genes, FDR = 3.20 E−03, FE = 2.47; Choi et al., [2016](#ajmgb32704-bib-0024){ref-type="ref"}; Supporting Information Table [S19](#ajmgb32704-supitem-0020){ref-type="supplementary-material"}).

Finally, we used the genomic coordinates from the *de novo* variations (DNVs) from whole genome sequencing of probands (1,392 males and 353 females ASD) and affected siblings (674 males and 206 females ASD; Yuen et al., [2017](#ajmgb32704-bib-0144){ref-type="ref"}) and compared them with SRY and SOX3 peak coordinates. If the regulation of binding sites of one or both proteins is important in the context of disease, we should observe a larger overlap of DNVs under the peaks than randomly. We built 1,000 random sets of genomic coordinates from each dataset peak with the same number of peaks and chromosome distribution and compared the overlaps as a control. Using the SRY peaks, we identified an enrichment of DNVs in the male probands with 242 DNVs (*p* value = 0.024, Supporting Information Figure [S9](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}a) and 184 DNVs (*p* value = 0.017) in the male affected siblings. This result was not observed using SOX3 peaks, resulting in 111 DNVs (*p* value = 0.173, Supporting Information Figure [S9](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}b) using probands and 83 DNVs (*p* value = 0.202) in the affected siblings. In the female dataset using SRY peaks, we identified an enrichment of DNVs with 78 DNVs in probands (*p* value = 0.004, Supporting Information Figure [S9](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}c) and 42 DNVs in affected siblings (*p* value = 0.682). In contrast, for SOX3 peaks, 36 of the DNVs in the probands were observed (*p* value = 0.069, Supporting Information Figure [S9](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}d), and 14 DNVs were observed in the affected siblings (*p* value = 0.968), representing no difference. To confirm that the SRY overlapping was higher because we used human SRY peaks dataset, we investigated the origins of SRY peaks. Using a human model, the 242 DNVs from male probands were under 57 (23.55%) SRY peaks, with eight peaks also identified in the mouse model. Another 184 (76.03%) DNVs were found to intersect with the mouse SRY peaks, and one (0.42%) DNV intersected with SRY peaks from the rats. The 78 DNVs from female probands were under 17 (22%) SRY peaks from a human model, and 61 (78%) DNVs were found to intersect with SRY peaks from the mouse model. This result shows that for the male ASD dataset, the context of SRY or SRY‐complex binding is important.

Half of the DNVs identified under SRY peaks in male (124, 51%) and female (39, 50%) samples are upstream from a known transcription start site (TSS; Supporting Information Figure [S10](#ajmgb32704-supitem-0001){ref-type="supplementary-material"}), and 23% of DNVs in male (*n* = 56) and female (*n* = 18) samples are downstream, up to 1 kb from TSS, suggesting that these variations could be in regulatory regions. Regarding DNVs under the SOX3 peaks, a smaller percentage is upstream from TSS in male (*n* = 30, 27%) and female (*n* = 6, 17%) samples, and only 9 (12%) and 5 (14%) DNVs are downstream, up to 1 kb, from TSS in male and female samples, respectively. Although SOX3 peaks are not overrepresented in DNVs in the ASD samples compared to the random sets, 72 (34%) of 214 genes, representing the 242 DNVs that are under SRY peaks, are also targets of the SOX3 protein.

3.9. Disruption of the coexpression module in male individuals with autism showed enrichment in the pathways related to stress and neurodevelopment {#ajmgb32704-sec-0024}
---------------------------------------------------------------------------------------------------------------------------------------------------

A coexpression network analysis was used for the SOX3/SRY set by comparing the prefrontal brain samples from 12 ASD and 15 control male individuals (Voineagu et al., [2011](#ajmgb32704-bib-0129){ref-type="ref"}). Female samples were excluded from this analysis, as the samples were scarce. There were no significant between‐group differences in age or *postmortem* interval (PMI; Wilcoxon test, *p* value \>0.05). We identified 13 modules in control samples, all of which were preserved with Z‐summaries ≥10, showing that their coexpressed network was robust. The 13 modules were evaluated in the ASD samples (Figure [6](#ajmgb32704-fig-0006){ref-type="fig"}, Supporting Information Table [S20](#ajmgb32704-supitem-0021){ref-type="supplementary-material"}), showing that the red and brown modules were disrupted. They were enriched in pathways related to ER‐nucleus signaling pathway, ER stress response, apoptosis, regulation of nervous system development and neuron differentiation (Table [6](#ajmgb32704-tbl-0006){ref-type="table"}, Supporting Information Tables [\[Link\]](#ajmgb32704-supitem-0022){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0023){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0024){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0025){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0026){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0027){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0028){ref-type="supplementary-material"}). This analysis is limited, as we applied the WGCNA on a subset of genes and substantial coexpression information may have been lost, biasing the modules identification.

![Module preservation analysis preservation analysis resulted in 13 gene modules, which are labeled with unique colors. These modules were generated using WGCNA with control samples. (a) Left panel shows the median preservation rank (y‐axis) in relation to the module size (x‐axis). Each circle represents a module labeled in different colors, with the lowest rank scores represented by brown (MedianRank = 11), black (MedianRank = 12), purple (MedianRank = 13), and red (MedianRank = 13) modules. The right panel shows the Z‐summary score (y‐axis) as a function of module size. The dashed lines represent thresholds 2 and 10: ≥10: High preservation; 2\< Z‐summary \<10: Moderate preservation; \<2: Low preservation. The least preserved modules are represented by brown (Z‐summary = 0.87) and red (Z‐summary = 1.3). (b) Scatter plots of kME of control (x‐axis) and autism (y‐axis) samples. Each dot corresponds to kME, which is the correlation of each gene in the module with the module eigenmode (eigengene‐based connectivity). The red dots represent the genes that showed greater differences between the ASD and CON samples. Higher correlations indicate that the internal module coexpression structure is more preserved. Only the brown and red modules were represented because they demonstrated the lowest cor.kME. Pearson correlation (cor.kME) and the corresponding *p* value are represented above the respective graphic. The upper panel represents the brown module, with 99 genes (cor = −0.18, *p* = .075), consisting of genes enriched in categories related to the stress response. The lower panel represents the red module, with 78 genes (cor = − 0.21, *p* = .065), consisting of genes enriched in categories primarily related to neurogenesis \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-390-g006){#ajmgb32704-fig-0006}

###### 

Functional enrichment analysis of least preserved modules between ASD and CON

  GO type                         GO category name                           GO ID        C       O    E      R       *p*
  ------------------------------- ------------------------------------------ ------------ ------- ---- ------ ------- ----------
  Brown module (*n* = 99 genes)                                                                                       
  Biological process              ER‐nucleus signaling pathway               GO:0006984   97      5    0.56   8.87    1.67E−02
  Biological process              Response to endoplasmic reticulum stress   GO:0034976   113     5    0.66   7.62    3.34E−02
  Biological process              Negative regulation of apoptotic process   GO:0043066   572     10   3.32   3.01    3.87E−02
  Cellular component              Synapse part                               GO:0044456   370     6    2      3.01    4.77E−02
  Disease                         HIV                                        PA447230     755     10   1.73   5.77    5.87E−05
  Disease                         Stress                                     PA445752     464     6    1.07   5.63    1.40E−03
  Disease                         HIV infections                             PA446213     382     5    0.88   5.7     2.90E−03
  Transcription factor            hsa_V\$HIF1_Q5                             2,120        242     7    0.56   12.6    1.29E−05
  Transcription factor            hsa_V\$PPAR_DR1_Q2                         2,248        257     7    0.59   11.87   1.63E−05
  Transcription factor            hsa_V\$HIF1_Q3                             2,273        225     5    0.52   9.68    4.00E−04
                                  hsa_TAATAAT,MIR‐126                        876          220     7    0.51   13.86   2.97E−06
  Red module (*n* = 78 genes)                                                                                         
  Biological process              Regulation of cell development             GO:0060284   495     10   2.3    4.35    1.18E−02
  Biological process              Regulation of synaptic plasticity          GO:0048167   96      5    0.45   11.21   1.18E−02
  Biological process              Regulation of nervous system development   GO:0051960   440     8    2.05   3.91    3.30E−02
  Biological process              Regulation of neuron differentiation       GO:0045664   331     7    1.54   4.55    3.30E−02
  Biological process              Neuron differentiation                     GO:0030182   990     12   4.6    2.61    3.81E−02
  Biological process              Generation of neurons                      GO:0048699   1,073   12   4.99   2.41    4.75E−02
  Disease                         Central nervous system diseases            PA443657     438     6    0.79   7.57    0.0003
  Disease                         Mental disorders                           PA447208     564     7    1.02   6.86    0.0003
  Transcription factor            hsa_GGGCGGR_V\$SP1_Q6                      2,452        2,891   24   5.23   4.59    4.06E−09
  Transcription factor            hsa_GCCATNTTG_V\$YY1_Q6                    2,459        419     5    0.76   6.6     1.20E−03

Abbreviations. C = number of reference genes in the category; E = expected number in the category; O = number of genes in the gene set and also in the category; *p* = *p* value adjusted by multiple test adjustment (FDR); R = ratio of enrichment.

Thus, we compared the SOX3/SRY set to the 12 modules built from a comprehensive dataset of 104 brain samples, containing 57 (40 unique) control individuals and 47 (32 unique) autistic individuals, from multiple cortical tissues (BA19, *n* = 62; BA10, *n* = 14; and BA44, *n* = 28; Gupta et al., [2014](#ajmgb32704-bib-0046){ref-type="ref"}). This analysis revealed enrichment for six modules, all related to glial or neuronal function biological processes (Table [7](#ajmgb32704-tbl-0007){ref-type="table"}). Three of six modules were already described as being related to ASD (mod1, mod5, and mod6; Gupta et al., [2014](#ajmgb32704-bib-0046){ref-type="ref"}). Mod1 and mod6 showed enrichment to functional categories related to nervous system development, synapses and neurotransmitter, while mod5 identified enrichment in categories related to immune system (Table [8](#ajmgb32704-tbl-0008){ref-type="table"}, Supporting Information Tables [\[Link\]](#ajmgb32704-supitem-0029){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0030){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0031){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0032){ref-type="supplementary-material"}). Similar analyses were performed with 24 modules built from the cortex brain samples of 48 control and 49 ASD individuals (Parikshak et al., [2016](#ajmgb32704-bib-0090){ref-type="ref"}). This analysis resulted in an enrichment of 10 modules, four of which were already associated with ASD, three of which were upregulated (CTX.M9, CTX.M19, and CTX.M20) and one downregulated (CTX.M16; Table [9](#ajmgb32704-tbl-0009){ref-type="table"}). The CTX.M9 and CTX.M20 modules were enriched in genes related to metabolism and development; only CTX.M9 was enriched in response to oxidative stress. CTX.M16 was composed of genes related to cognition and the regulation of neurotransmitter signaling and neuron development. CTX.M19 showed enrichment in immune system stimulation (Supporting Information Tables [\[Link\]](#ajmgb32704-supitem-0033){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0034){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0035){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0036){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0037){ref-type="supplementary-material"}, [\[Link\]](#ajmgb32704-supitem-0038){ref-type="supplementary-material"}).

###### 

Enrichment analysis of coexpressed ASD modules

                  SOX3/SRY   Gupta modules[a](#ajmgb32704-note-0015){ref-type="fn"}                                                 
  ------- ------- ---------- -------------------------------------------------------- -------------- -------------- ---- ---------- ---------------
  mod1    1,587   172        1.35                                                     **1.00E−04**   **2.00E−04**   −    8.29E−03   Neuronal
  mod2    1,290   166        1.56                                                     **1.00E−04**   **2.00E−04**   \+   8.72E−01   Neuronal
  mod3    1,046   134        1.56                                                     **1.00E−04**   **2.00E−04**   −    7.61E−02   Glial
  mod4    758     65         1.12                                                     1.89E−01       2.84E−01       −    7.64E−01   Translational
  mod5    747     94         1.54                                                     **1.00E−04**   **2.00E−04**   \+   9.64E−04   Glial
  mod6    644     88         1.67                                                     **1.00E−04**   **2.00E−04**   \+   6.39E−03   Neuronal
  mod7    590     79         1.63                                                     **1.00E−04**   **2.00E−04**   \+   1.08E−01   Glial
  mod8    446     38         1.07                                                     3.46E−01       3.77E−01       \+   3.64E−02   Transcription
  mod9    368     39         1.3                                                      5.39E−02       9.24E−02       \+   2.55E−01   Transcription
  mod10   267     23         1.11                                                     3.35E−01       3.77E−01       −    6.47E−01   Translational
  mod11   237     22         1.11                                                     3.38E−01       3.77E−01       \+   5.84E−02   Glial
  mod12   83      2          0.564                                                    8.79E−01       8.79E−01       \+   1.43E−01   Neuronal

Direction: A positive (+) sign indicates upregulated gene expression in autism cases.

\#: Number of overlapping genes. FE = fold enrichment.

Bold: *p* value calculated in 10,000 permutations.

Data provided by Gupta et al. ([2014](#ajmgb32704-bib-0046){ref-type="ref"}).

###### 

Functional enrichment analysis of SOX3/SRY set compared to Gupta modules related to ASD

  M[a](#ajmgb32704-note-0017){ref-type="fn"}   GO type      GO ID                                                     GO category name                                                 C     O        E       R          *p*
  -------------------------------------------- ------------ --------------------------------------------------------- ---------------------------------------------------------------- ----- -------- ------- ---------- ----------
  mod1                                         BP           GO:0006813                                                Potassium ion transport                                          215   48       17.26   2.78       1.93E−08
  BP                                           GO:0006836   Neurotransmitter transport                                193                                                              40    15.50    2.58    1.65E−06   
  BP                                           GO:0050890   Cognition                                                 251                                                              43    20.15    2.13    8.10E−05   
  BP                                           GO:0007626   Locomotory behavior                                       188                                                              33    15.10    2.19    4.81E−04   
  BP                                           GO:0007215   Glutamate receptor signaling pathway                      71                                                               17    5.70     2.98    1.01E−03   
  BP                                           GO:0002209   Behavioral defense response                               33                                                               10    2.65     3.77    4.13E−03   
  BP                                           GO:0006914   Autophagy                                                 437                                                              55    35.09    1.57    1.08E−02   
  CC                                           GO:0098793   Presynapse                                                317                                                              77    27.45    2.81    0.00E+00   
  Phenotype                                    HP:0002167   Neurological speech impairment                            697                                                              92    50.22    1.83    4.89E−07   
  Phenotype                                    HP:0100851   Abnormal emotion/affect behavior                          436                                                              56    31.42    1.78    3.88E−04   
  Phenotype                                    HP:0000708   Behavioral abnormality                                    900                                                              96    64.85    1.48    3.88E−04   
  Phenotype                                    HP:0001263   Global developmental delay                                888                                                              94    63.99    1.47    6.39E−04   
  Phenotype                                    HP:0002011   Morphological abnormality of the central nervous system   1,691                                                            153   121.85   1.26    1.84E−03   
  Phenotype                                    HP:0012433   Abnormal social behavior                                  69                                                               14    4.97     2.82    1.29E−02   
  Phenotype                                    HP:0001249   Intellectual disability                                   1,039                                                            99    74.87    1.32    1.86E−02   
  Phenotype                                    HP:0100852   Abnormal fear/anxiety‐related behavior                    103                                                              17    7.42     2.29    3.13E−02   
  Phenotype                                    HP:0012447   Abnormal myelination                                      269                                                              33    19.38    1.70    4.30E−02   
  mod5                                         BP           GO:0034340                                                Response to type I interferon                                    79    31       3.38    9.18       0.00E+00
  BP                                           GO:0098542   Defense response to other organism                        443                                                              51    18.93    2.69    2.46E−08   
  BP                                           GO:0007249   I‐kappaB kinase/NF‐kappaB signaling                       257                                                              35    10.98    3.19    1.78E−07   
  BP                                           GO:0034341   Response to interferon‐gamma                              155                                                              23    6.62     3.47    2.23E−05   
  BP                                           GO:0045088   Regulation of innate immune response                      349                                                              36    14.91    2.41    9.98E−05   
  BP                                           GO:0032606   Type I interferon production                              111                                                              16    4.74     3.37    1.14E−03   
  BP                                           GO:0070741   Response to interleukin‐6                                 29                                                               8     1.24     6.46    1.14E−03   
  BP                                           GO:0002253   Activation of immune response                             482                                                              41    20.60    1.99    1.14E−03   
  BP                                           GO:0035456   Response to interferon‐beta                               24                                                               7     1.03     6.82    1.95E−03   
  BP                                           GO:0032612   Interleukin‐1 production                                  68                                                               10    2.91     3.44    1.54E−02   
  mod6                                         BP           GO:0099531                                                Presynaptic process involved in chemical synaptic transmission   154   18       4.94    3.64       8.43E−04
  BP                                           GO:0001505   Regulation of neurotransmitter levels                     192                                                              19    6.16     3.08    3.47E−03   
  BP                                           GO:0051962   Positive regulation of nervous system development         443                                                              30    14.22    2.11    1.08E−02   
  BP                                           GO:0044708   SinglE−organism behavior                                  393                                                              26    12.62    2.06    2.79E−02   
  CC                                           GO:0098793   Presynapse                                                317                                                              29    10.70    2.71    1.37E−04   
  CC                                           GO:0030424   Axon                                                      379                                                              29    12.79    2.27    1.51E−03   
  CC                                           GO:0098984   Neuron to neuron synapse                                  193                                                              16    6.51     2.46    3.01E−02   
  MF                                           GO:0016247   Channel regulator activity                                128                                                              15    4.28     3.50    3.20E−03   

Abbreviations. BP = Biological Process, CC = Cellular Component, MC = Molecular Component, C = number of reference genes in the category, O = number of genes in the gene set and also in the category, E = expected number in the category, R = Ratio of enrichment; *p* = *p* value adjusted by multiple test adjustment (FDR).

Data provided by Gupta and collaborators (Gupta et al., [2014](#ajmgb32704-bib-0046){ref-type="ref"}).

###### 

Enrichment analysis of coexpressed ASD modules

                    SOX3/SRY                                         
  --------- ------- ---------- ------- -------------- -------------- -------
  CTX.M1    321     28         1.08    3.61E−01       5.42E−01       
  CTX.M2    1,468   151        1.3     **6.00E−04**   **3.60E−03**   
  CTX.M3    1,211   132        1.31    **8.00E−04**   **3.84E−03**   
  CTX.M4    233     23         1.22    1.91E−01       3.27E−01       \[−\]
  CTX.M5    108     17         1.9     **7.50E−03**   **2.00E−02**   
  CTX.M6    69      0          0       1.00E+00       1.00E+00       
  CTX.M7    98      15         2.07    **5.80E−03**   **2.00E−02**   
  CTX.M8    86      8          1.14    4.06E−01       5.51E−01       
  CTX.M9    507     71         1.7     **1.00E−04**   **8.00E−04**   \[+\]
  CTX.M10   257     21         1.01    5.15E−01       6.18E−01       \[−\]
  CTX.M12   172     24         1.68    **6.90E−03**   **2.00E−02**   
  CTX.M13   171     12         1       5.48E−01       6.26E−01       
  CTX.M14   127     5          0.524   9.70E−01       1.00E+00       
  CTX.M15   130     12         1.1     4.13E−01       5.51E−01       
  CTX.M16   278     34         1.46    **1.69E−02**   **4.06E−02**   \[−\]
  CTX.M17   191     23         1.48    **3.36E−02**   7.33E−02       
  CTX.M18   300     31         1.26    1.13E−01       2.12E−01       
  CTX.M19   274     35         1.53    **7.40E−03**   **2.00E−02**   \[+\]
  CTX.M20   331     63         2.32    **1.00E−04**   **8.00E−04**   \[+\]
  CTX.M21   108     9          1.03    5.07E−01       6.18E−01       
  CTX.M22   221     22         1.32    1.15E−01       2.12E−01       
  CTX.M23   228     15         0.842   7.92E−01       8.64E−01       
  CTX.M24   1,234   92         1.06    2.79E−01       4.46E−01       
  CTX.M25   813     117        1.75    **1.00E−04**   **8.00E−04**   

\#: Number of overlapping genes. FE = fold enrichment.

Bold**:** *p* value (10,000 permutations) or FDR ≤ 0.05.

Results from Parikshak et al. ([2016](#ajmgb32704-bib-0090){ref-type="ref"}).

4. DISCUSSION {#ajmgb32704-sec-0025}
=============

There was evidence supporting the hypothesis that sexual dimorphism appears before gonadal formation in animal models, suggesting that sex chromosomes play a role in the differences between sexes (Arnold, [2004](#ajmgb32704-bib-0003){ref-type="ref"}; Arnold & Burgoyne, [2004](#ajmgb32704-bib-0004){ref-type="ref"}; Wolstenholme, Rissman, & Bekiranov, [2013](#ajmgb32704-bib-0138){ref-type="ref"}). The regulatory capacities exerted by SRY (Y‐linked protein) and SOX3 (X‐linked protein) in the brain and their capacity to regulate autosomal genes are well established today (Collignon et al., [1996](#ajmgb32704-bib-0027){ref-type="ref"}; Mayer et al., [2000](#ajmgb32704-bib-0076){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}; Reisert & Pilgrim, [1991](#ajmgb32704-bib-0101){ref-type="ref"}). Therefore, we hypothesized that genes regulated by X and, Y factors in a differential manner could produce adaptive sex changes but also contribute to the differential risk for neurodevelopmental disorders. Accordingly, although the regulation exerted by *SOX3* was not considered to be a sex‐specific factor, males have two different regulatory proteins, whereas females have one, suggesting the existence of a group of genes that are potentially associated with the sex‐biased prevalence in neurodevelopmental disorders.

We were limited by the available data in the literature, which provided only SRY and SOX3 target genes in different cell types and from distinct species. Ideally, to understand the role of SOX3 and SRY in neurodevelopment, the same cell type from the brains of a single species should be analyzed. To overcome this difficulty, we first analyzed datasets from only mice

In this analysis, we selected target genes from both proteins expressed during different brain periods. As the SRY data came from gonad cells, to increase the certainty that our selected datasets would be more associated with brain expression, we compared them with the patterns of brain and testis specific tissue expression. Although we have used data from adult brains and testes, the SOX3 and SOX3/SRY targets were enriched for only brain expression patterns, and even for exclusive SRY targets, no specific pattern of testis expression was observed.

SOX3 has been clearly involved in brain development, hence the overrepresentation of its targets in all neural cells and brain tissue was expected (Cheah & Thomas, [2015](#ajmgb32704-bib-0022){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}). Likewise, exclusive targets of SRY were enriched in most neural cell types. However, the SOX3/SRY target genes demonstrated biased expression in the brain, only for genes with specific expression in cortical neuron differentiation. As astrocytes and oligodendrocytes appear later during neurodevelopment (Budday, Steinmann, & Kuhl, [2015](#ajmgb32704-bib-0017){ref-type="ref"}), we could speculate whether the action of SOX3 and SRY on the same target genes could be more restricted to earlier neurodevelopmental periods.

The SOX3/SRY set showed enrichment for functional and phenotypic categories related to neurodevelopment, neuron projection, craniofacial abnormalities, head size, behavior and motor coordination, features with clear sexual dimorphism (Giedd, Castellanos, Rajapakse, Vaituzis, & Rapoport, [1997](#ajmgb32704-bib-0040){ref-type="ref"}; Ngun, Ghahramani, Sánchez, Bocklandt, & Vilain, [2011](#ajmgb32704-bib-0087){ref-type="ref"}; Sacher, Neumann, Okon‐Singer, Gotowiec, & Villringer, [2013](#ajmgb32704-bib-0104){ref-type="ref"}). Only exclusive targets of SRY or SOX3 were enriched in the astrocytes, and only exclusive SRY targets were enriched for microglia, suggesting that our approach was able to identify potentially different regulatory mechanisms in different cell types that are important for brain and sex differences (Lenz & McCarthy, [2015](#ajmgb32704-bib-0067){ref-type="ref"}).

After confirming that SRY and SOX3 had highly conserved HMG‐box among species, according to protein alignment and literature evidence (Araujo et al., [2015](#ajmgb32704-bib-0002){ref-type="ref"}; Collignon et al., [1996](#ajmgb32704-bib-0027){ref-type="ref"}; Wood & Episkopou, [1999](#ajmgb32704-bib-0139){ref-type="ref"}), we improved our datasets using mouse, rat and human data to identify the target genes and selected only those genes expressed during human brain development (up to 7 years of age). Moreover, using the data from Lesch et al. ([2016](#ajmgb32704-bib-0068){ref-type="ref"}), we showed that the SOX3/SRY target genes were under the same regulation programs, independently of the analyzed species. In SRY, this regulatory potential was demonstrated by the ectopic activation of human SRY in mice, and this activation was able to alter gene expression in the brain, heart, lung, and liver (Kido, Sun, & Lau, [2017](#ajmgb32704-bib-0057){ref-type="ref"}).

The SOX3/SRY target genes were related to brain development, metabolism and DNA transcriptional regulation, suggesting that they could be important in determining the metabolic differences between sexes. Different brain expression patterns between sexes have been previously reported in the literature in both human and animal models, particularly during neurodevelopment (Ellegren & Parsch, [2007](#ajmgb32704-bib-0038){ref-type="ref"}; Peper & Koolschijn, [2012](#ajmgb32704-bib-0091){ref-type="ref"}; Reinius & Jazin, [2009](#ajmgb32704-bib-0100){ref-type="ref"}; Trabzuni et al., [2013](#ajmgb32704-bib-0124){ref-type="ref"}; Xu, Burgoyne, & Arnold, [2002](#ajmgb32704-bib-0141){ref-type="ref"}; Ziats & Rennert, [2014](#ajmgb32704-bib-0149){ref-type="ref"}; Ziats & Rennert, [2013](#ajmgb32704-bib-0148){ref-type="ref"}).

Our SOX3/SRY set was overrepresented in eight neurodevelopmental coexpression modules; most demonstrated higher gene expression levels during the early‐gestation and mid‐gestation periods (Parikshak et al., [2013](#ajmgb32704-bib-0089){ref-type="ref"}). The exclusive targets from SOX3 and SRY, except for the sets that overlap with the SOX3/SRY targets, were more associated with the post‐birth expression modules. Parikshak previously described that early gestational modules were more related to processes associated with cell division and differentiation (promoting organogenesis), whereas the process from mid gestational period to after birth was more associated with synaptic transmission and regulation of plasticity. To better understand the putative action of SOX3 and SRY on the same targets, we focused on the modules in the intrauterine period that were enriched in the SOX3/SRY set, independently of sex hormone modulation (Lombardo et al., [2012](#ajmgb32704-bib-0073){ref-type="ref"}; McCarthy, Arnold, Ball, Blaustein, & De Vries, [2012](#ajmgb32704-bib-0078){ref-type="ref"}; Neufang et al., [2009](#ajmgb32704-bib-0086){ref-type="ref"}; Peper & Koolschijn, [2012](#ajmgb32704-bib-0091){ref-type="ref"}).

Biological processes related to zinc ion binding, known to play important roles in brain development, were overrepresented in the modules (Levenson & Morris, [2011](#ajmgb32704-bib-0069){ref-type="ref"}; McKenzie, Fosmire, & Sandstead, [1975](#ajmgb32704-bib-0079){ref-type="ref"}; Sandstead, [2003](#ajmgb32704-bib-0108){ref-type="ref"}; Sandstead, Fosmire, McKenzie, & Halas, [1975](#ajmgb32704-bib-0109){ref-type="ref"}). Zinc binding deficiency during the prenatal period results in impaired brain growth, which also affects cognitive functions and behavior (Bhatnagar & Taneja, [2001](#ajmgb32704-bib-0013){ref-type="ref"}; Hagmeyer, Haderspeck, & Grabrucker, [2014](#ajmgb32704-bib-0047){ref-type="ref"}; Kirksey et al., [1991](#ajmgb32704-bib-0059){ref-type="ref"}, [1994](#ajmgb32704-bib-0060){ref-type="ref"}; Tyszka‐Czochara et al., [2014](#ajmgb32704-bib-0126){ref-type="ref"}). Low serum zinc levels were also observed in neuropsychiatric disorders (Pfaender & Grabrucker, [2014](#ajmgb32704-bib-0093){ref-type="ref"}), including ASD (Grabrucker, [2014](#ajmgb32704-bib-0042){ref-type="ref"}). In rats, prenatal zinc deficiency yielded more aggressive female offspring compared to controls, a phenotype that was not observed in male offspring (Halas, Reynolds, & Sandstead, [1977](#ajmgb32704-bib-0048){ref-type="ref"}). Zinc plays a role in synaptic plasticity (Grabrucker et al., [2011](#ajmgb32704-bib-0043){ref-type="ref"}), which is different between the sexes (Kang et al., [2011](#ajmgb32704-bib-0056){ref-type="ref"}; Mottron et al., [2015](#ajmgb32704-bib-0083){ref-type="ref"}), suggesting that modulation of zinc‐related pathways might be sex‐specific. Using Kang data (Kang et al., [2011](#ajmgb32704-bib-0056){ref-type="ref"}), the analysis of sex biased expression during brain development supported a possible role of the SOX3/SRY set, independently of hormones.

Moreover, zinc is involved with DNA methylation mechanisms (Hong, Keen, Mizuno, Johnston, & Tamura, [2000](#ajmgb32704-bib-0051){ref-type="ref"}; Jing et al., [2015](#ajmgb32704-bib-0054){ref-type="ref"}; Wallwork & Duerre, [1985](#ajmgb32704-bib-0131){ref-type="ref"}). We demonstrated that SOX3/SRY and SRY sets were enriched for genes differentially methylated between sexes during neurodevelopment. Again, approximately 60% of these differentially methylated CpG sites are located precisely over SRY peaks; this finding is interesting because SRY plays an epigenetic role in several organisms (Clement, Bhandari, Sadler‐Riggleman, & Skinner, [2011](#ajmgb32704-bib-0025){ref-type="ref"}; Dewing et al., [2006](#ajmgb32704-bib-0033){ref-type="ref"}; Sekido, [2014](#ajmgb32704-bib-0113){ref-type="ref"}; Wu, Chen, Li, Lau, & Shih, [2009](#ajmgb32704-bib-0140){ref-type="ref"}).

We observed that the SRY peaks were larger than the SOX3 peaks, what could result in bias, as larger peaks have a higher chance to overlap with a CpG site. However, analyses of the distribution of the distance of the SOX3/SRY peaks, in relation to the CpG sites, revealed that most of the SOX3 peaks were located more than 3 kb upstream or downstream, indicating that even if the SOX3 peaks were as large as the SRY peaks (1,879 nucleotides), it would not overlap with the CpG sites. Thus, the SOX3 regulatory role is likely to be something other than the regulation provided by CpG site methylation, including in neurodevelopment (Bergsland et al., [2011](#ajmgb32704-bib-0010){ref-type="ref"}; Brunelli et al., [2003](#ajmgb32704-bib-0016){ref-type="ref"}; Bylund, Andersson, Novitch, & Muhr, [2003](#ajmgb32704-bib-0018){ref-type="ref"}; McAninch & Thomas, [2014](#ajmgb32704-bib-0077){ref-type="ref"}; Sutton et al., [2011](#ajmgb32704-bib-0118){ref-type="ref"}).

The differential modulation exerted by SRY and SOX3 was reinforced by the network analyses. We investigated just a small fraction of each network and found a considerable difference in the TF distribution. While the SOX3 network showed TFs that were closely linked to neurodevelopment, the SRY network showed a larger network with a higher number of TF related to a wide range of biological processes, including cell cycle, chromatin remodeling, and neural development. For instance, differences in regulation were observed in the renin *(REN)* promoter, where SRY and SOX3 promote and repress activation, respectively (Araujo et al., [2015](#ajmgb32704-bib-0002){ref-type="ref"}). This finding indicates that even if both proteins target the same gene, the regulation that each exerts can differ, particularly in the context of sex‐biased diseases.

To investigate these findings in the context of neuropsychiatry disorders, we selected ASD as a model, as it is a sex‐biased neurodevelopmental disorder with a ratio of 4:1 (boys:girls; Werling, [2016](#ajmgb32704-bib-0135){ref-type="ref"}). Two groups of developmentally regulated expression modules have been associated with ASD: those most highly expressed during early pregnancy and those with higher expression during the stage from late pregnancy to after birth (Wang, Zhao, Lachman, & Zheng, [2018](#ajmgb32704-bib-0133){ref-type="ref"}). Exclusive SRY or SOX3 gene sets are associated with postbirth modules, while the SOX3/SRY set is most related to the early periods of neurodevelopment. Genes from neurodevelopmental modules M2 and M3, which were also overrepresented in our SOX3/SRY set, were reported to be enriched within RDNV from ASD exome studies (Parikshak et al., [2013](#ajmgb32704-bib-0089){ref-type="ref"}), suggesting that our SOX3/SRY set could be important in the context of ASD in the early period of gestation.

To reinforce our hypothesis, early differences in brain cell development between sexes were observed, even before hormonal production (Arnold & Burgoyne, [2004](#ajmgb32704-bib-0004){ref-type="ref"}; Dewing, Shi, Horvath, & Vilain, [2003](#ajmgb32704-bib-0034){ref-type="ref"}; Rinn & Snyder, [2005](#ajmgb32704-bib-0102){ref-type="ref"}). The early and early‐mid periods (8--17 PCW) are important to neuronal proliferation and migration (Stiles & Jernigan, [2010](#ajmgb32704-bib-0117){ref-type="ref"}; Tau & Peterson, [2010](#ajmgb32704-bib-0120){ref-type="ref"}), and impairments in neuronal migration are a characteristic that was observed in ASD (Reiner, Karzbrun, Kshirsagar, & Kaibuchi, [2016](#ajmgb32704-bib-0099){ref-type="ref"}). Moreover, we showed that although all three datasets were enriched for genes that do not tolerate variations, as previously demonstrated for ASD genes (Petrovski et al., [2013](#ajmgb32704-bib-0092){ref-type="ref"}), only the SOX3/SRY target was enriched in the dataset of genes intolerant for mutations involved in the early fetal brain development, reinforcing the hypothesis that they are important for programing early male/female brain development.

One example of an ASD‐associated risk gene that has shown sex‐differential effects is *MAOA*, in which genetic variants in the promoter region of *MAOA* have been shown to interfere with an SRY binding site and to pose a higher risk to males (Dimas et al., [2012](#ajmgb32704-bib-0035){ref-type="ref"}; Verma et al., [2014](#ajmgb32704-bib-0127){ref-type="ref"}). We complemented our analyses using ASD databases to investigate the potential of this differential regulation. We found a higher proportion of DNVs over SRY peaks compared to random peaks in both male probands and affected sibling samples, suggesting that these variants can interfere with the binding sites of SRY or SRY‐complex in male individuals. This finding was observed in female datasets with large numbers of DNVs under SRY‐peaks, compared to random sets; however, females do not harbor the *SRY* gene. We cannot confirm whether these variations are located in functional sites, as we did not investigate the putative TF that could bind to these sites. Although this result was not observed while investigating the SOX3 peaks, 34% of the genes with DNVs under SRY peaks are also targets of the SOX3 protein, suggesting the involvement of SOX3/SRY in this dataset. Our results suggest that both proteins play differential regulatory roles between sexes during brain development, with their targets overrepresented in ASD datasets.

Moreover, we observed differences in the coexpression gene network of the SOX3/SRY dataset between adult ASD and controls. Indeed, two modules showed low preservation scores, consisting of categories that were primarily related to stress, synapses and neuronal development. Identification of the categories associated with the endoplasmic reticulum and apoptosis regulation indicated pathways that were also related to the stress response (Hicks & Machamer, [2005](#ajmgb32704-bib-0049){ref-type="ref"}; Schröder, [2008](#ajmgb32704-bib-0111){ref-type="ref"}), along with genes regulated by *PPAR* and *HIF1* TFs. *PPAR* demonstrated increased expression levels during pregnancy after stress exposure in male but not female placentas (Holler, Westin, Jiricny, & Schaffner, [1988](#ajmgb32704-bib-0050){ref-type="ref"}; Mueller & Bale, [2008](#ajmgb32704-bib-0084){ref-type="ref"}), and *HIF1* showed increased expression under oxidative stress (Pialoux et al., [2009](#ajmgb32704-bib-0094){ref-type="ref"}; Zhu et al., [2003](#ajmgb32704-bib-0147){ref-type="ref"}).

Several studies have demonstrated that impairments in neurodevelopment and synapse formation associated with ASD (Bourgeron, [2015](#ajmgb32704-bib-0014){ref-type="ref"}; Codina‐Solà et al., [2015](#ajmgb32704-bib-0026){ref-type="ref"}; De Rubeis et al., [2014](#ajmgb32704-bib-0031){ref-type="ref"}; Devlin & Scherer, [2012](#ajmgb32704-bib-0032){ref-type="ref"}; Sanders et al., [2015](#ajmgb32704-bib-0107){ref-type="ref"}; Voineagu et al., [2011](#ajmgb32704-bib-0129){ref-type="ref"}) were also associated with sex bias models of prenatal stress exposure (Bale & Epperson, [2015](#ajmgb32704-bib-0007){ref-type="ref"}; Murmu et al., [2006](#ajmgb32704-bib-0085){ref-type="ref"}; Xu et al., [2013](#ajmgb32704-bib-0142){ref-type="ref"}; Zagron & Weinstock, [2006](#ajmgb32704-bib-0145){ref-type="ref"}).

Implications of epigenetics mechanisms underlying sex models have already been demonstrated in healthy humans (Maschietto et al., [2017](#ajmgb32704-bib-0074){ref-type="ref"}) and those under stressful conditions (Mueller & Bale, [2008](#ajmgb32704-bib-0084){ref-type="ref"}; Pilsner et al., [2012](#ajmgb32704-bib-0095){ref-type="ref"}; Tobi et al., [2009](#ajmgb32704-bib-0122){ref-type="ref"}), with males frequently demonstrating worse outcomes (Bale & Epperson, [2015](#ajmgb32704-bib-0007){ref-type="ref"}; Wainstock, Shoham‐Vardi, Glasser, Anteby, & Lerner‐Geva, [2015](#ajmgb32704-bib-0130){ref-type="ref"}; Weinstock, [2011](#ajmgb32704-bib-0134){ref-type="ref"}) In addition, Y chromosome regulation is affected by stress conditions, as exemplified by exposure to heavy metals, resulting in upregulation of SRY genes (Glahn et al., [2008](#ajmgb32704-bib-0041){ref-type="ref"}) and activation of catecholamine synthesis, in a hormone‐independent manner (Lee & Harley, [2012](#ajmgb32704-bib-0064){ref-type="ref"}). *SP1* (TF) was identified in the SOX3/SRY set and SRY‐network. The *SP1* binding site has a CpG, which can be affected by DNA methylation (Douet, Heller, & Le Saux, [2007](#ajmgb32704-bib-0036){ref-type="ref"}; Holler et al., [1988](#ajmgb32704-bib-0050){ref-type="ref"}; Zhu et al., [2003](#ajmgb32704-bib-0147){ref-type="ref"}) and acts synergistically with SRY (Sekido, [2014](#ajmgb32704-bib-0113){ref-type="ref"}; Wu et al., [2009](#ajmgb32704-bib-0140){ref-type="ref"}). Evidence indicates that promoter regions *DNMT3A* and *B* provide binding sites for SRY (Yanagisawa, Ito, Yuasa, & Maruyama, [2002](#ajmgb32704-bib-0143){ref-type="ref"}), suggesting that modulations in *SRY* expression could affect methylation patterns. *EP300*, a histone acetyltransferase, was identified in the SRY network, as a partner that modifies the chromatin state. Together this evidence suggests that SRY may recruit or regulate epigenetic factors under a stress response.

Contributions to the sex‐skewed prevalence of ASD seem to be related to naturally sexually dimorphic processes, which could modulate the impact of variants in a sex specific manner (Werling, [2016](#ajmgb32704-bib-0135){ref-type="ref"}; Werling, Parikshak, & Geschwind, [2016](#ajmgb32704-bib-0136){ref-type="ref"}). We provided support for this hypothesis and suggested that sex‐differential regulation exerted solely by SRY or in combination with SOX3 in different cells or gestation time could be a contributing factor associated with male stress exposure vulnerability (Wainstock et al., [2015](#ajmgb32704-bib-0130){ref-type="ref"}).

We are aware that our work has limitations, such as combining datasets from different species, requiring a new annotation pipeline that does not cover all data. In addition, the SOX3 ChIP‐seq experiments were performed in neuronal cells, whereas the SRY experiments were performed using gonadal cells. Thus, we first evaluated SRY peaks in a murine model, which has clear evidence of differential regulation exerted by sex chromosome with the "four core genotype" model (Arnold & Chen, [2009](#ajmgb32704-bib-0005){ref-type="ref"}). Some studies have modest sample sizes, which may interfere with the identification of differentially expressed or methylated genes during neurodevelopment. We only used ASD as a model, therefore, we cannot conclude whether our findings can be extended to other neurodevelopmental disorders.

5. CONCLUSIONS {#ajmgb32704-sec-0026}
==============

While the hypothesis of the sex chromosome complement is not new, we provided a new perspective in which the sex chromosomes could contribute to the sex bias prevalence in ASD, in addition to genetic variation, skewed X inactivation and escaping X chromosome genes. The regulatory roles of SOX3 and SRY over autosomal genes could be attributed in part to their specific partners during brain development. Although we cannot predict how much the sex chromosomes contribute to ASD, we provide a mechanism that explores the effect of sex chromosome genes and their regulatory roles over autosomal genes that can contribute to male bias in ASD and possibly to other neurodevelopmental disorders.
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